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ABSTRACT 
 
SARAH J. STEIN:  The role of NF-κB in BCR-ABL-driven oncogenic transformation and in 
hematopoiesis 
(Under the direction of Dr. Albert Baldwin) 
 
 
Chronic myeloid leukemia is a malignant clonal disorder of hematopoietic stem cells 
that results in increased and deregulated growth of myeloid cells.  About 95% of CML cases 
arise from the formation of the Philadelphia (Ph) chromosome, resulting in the expression of 
BCR-ABL, an oncoprotein with constitutive tyrosine kinase activity that drives oncogenesis.  
Current therapeutics for CML includes the BCR-ABL inhibitor, imatinib, which results in 
molecular remission in only 4% of patients.  Drug resistance also occurs in CML through 
point mutations in BCR-ABL itself, or through the upregulation of secondary signaling 
pathways.  Therefore, insight into novel therapeutic targets is needed for the treatment of 
CML.  Previous work has shown that BCR-ABL expression induces the activation of a 
dimeric transcription factor, NF-κB, and that its activity is required for efficient cellular 
transformation by BCR-ABL.  Here, we show that BCR-ABL utilizes NF-κB for survival of 
transformed cells, and for transformation to initiate to disease in vivo.  Due to the role of NF-
κB activity in the development and function of numerous hematopoietic cell types, we also 
investigate the role of classical NF-κB subunit, p65, in normal hematopoiesis.  Results 
indicate that the loss of p65 in the hematopoietic compartment leads to defects in 
hematopoiesis due to loss of hematopoietic stem cell homeostasis and the activation of 
alternative signaling pathways.  Together, these data show that p65 is an important regulator
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of hematopoiesis.  These data indicate that therapeutics involving the inhibition of NF-κB, 
although promising for the treatment of CML, should be used with caution. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Summary 
Chronic myeloid leukemia (CML) is initiated by the expression of BCR-ABL, an 
oncoprotein with constitutive tyrosine kinase activity that drives oncogenesis.  Current 
therapeutics for CML include the BCR-ABL inhibitor, imatinib, which results in complete 
hematologic response in 98% (Druker et al., 2006), but molecular remission in only 4%, of 
patients (Hughes et al., 2003).  Drug resistance also occurs in CML through point mutations 
in BCR-ABL itself, or through the upregulation of secondary signaling pathways.  Therefore, 
insight into novel therapeutic targets is needed for the treatment of CML.  Previous work has 
shown that BCR-ABL expression induces the activation of a dimeric transcription factor, 
NF-κB, and that its activity is required for efficient cellular transformation by BCR-ABL 
(Reuther et al., 1998).  Here, we show that BCR-ABL utilizes NF-κB for survival of 
transformed cells, and for transformation to initiate to disease in vivo. 
Due to the role of NF-κB activity in the development and function of numerous 
hematopoietic cell types ((Bottero et al., 2006; Gerondakis et al., 1999); see Table 1), we 
also investigate the role of classical NF-κB subunit, p65, in normal hematopoiesis.  We show 
that loss of p65 in the hematopoietic compartment of animals leads to skewed cell 
distribution, extramedullary hematopoiesis, and activation of alternative signaling pathways.  
p65 null hematopoietic stem cells (HSCs) show defects in repopulation ability, due to 
potential defects in differentiation or self-renewal.  Gene expression data show that p65 null 
HSCs upregulate a myeloid differentiation program, and alter expression of genes involved 
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in proliferation to increase proliferative capacity.  Together, these data show that p65 is an 
important regulator of hematopoiesis. 
 
1.2 NF-κB signaling in inflammation and disease 
            NF-κB is an inducible family of dimeric transcription factors comprised of five 
family members: p65 (RelA), RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2).  
These proteins share a conserved N-terminal Rel homology domain, which controls DNA 
binding, dimerization and interaction with inhibitory IκB proteins.  NF-κB is held in an 
inactive state by IκB.  NF-κB is typically activated through one of two distinct pathways.  In 
the classical pathway, the p50/p65 heterodimer is induced through the activation of the IκB 
kinase (IKK) complex, which contains two catalytic subunits, IKKα and IKKβ, and a 
regulatory subunit, IKKγ.  IKK phosphorylates IκBα, causing it to become ubiquitinated and 
subsequently degraded, allowing NF-κB to translocate to the nucleus.  In the alternative 
pathway, IKKα homodimers are activated and subsequently phosphorylate p100.  This results 
in the proteolytic processing of p100 to p52 and allows p52/RelB to translocate to the 
nucleus.  p65, RelB and c-rel each contain a transactivation domain (TAD) near the C-
terminus, which facilitates the recruitment of coactivators.  p52 and p50 lack a TAD and 
binding of homodimers to promoter regions can lead to repression of gene expression 
(Hayden and Ghosh, 2004).  Once in the nucleus, NF-κB is known to regulate the expression 
of a variety of genes, including those encoding cytokines and cytokine receptors, 
inflammatory genes and antiapoptotic proteins (Hayden and Ghosh, 2004; Bassères and 
Baldwin, 2006)). 
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Figure 1.1. The classical (left) and alternative (right) NF-κB signaling pathways. 
 
            Multiple signaling pathways lead to the activation of NF-κB.  Generally, these 
pathways activate the IKK complex, resulting in degradation of IκB or modification of p100, 
allowing NF-κB to enter the nucleus and regulate gene expression.  In response to 
inflammation, NF-κB is known to promote cell survival through the transcription of 
antiapoptotic genes, such as the cIAPs, which directly inhibit caspases, and genes that 
indirectly inhibit apoptosis through the regulation of other signaling pathways.  For example, 
the TNFα signaling pathway results in rapid activation of NF-κB through the classical 
pathway upon binding of TNFα to its receptor.  NF-κB then inhibits the activation of c-jun 
N-terminal kinase (JNK), which can promote apoptosis in response to prolonged activation 
(Hayden and Ghosh, 2004).  Furthermore, NF-κB is also important for regulating the level of 
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reactive oxygen species (ROS) in cells exposed to TNFα through the upregulation of 
antioxidant genes (Kamata et al., 2005; Tang et al., 2001). 
            In cancer, NF-κB is known to promote oncogenesis through the upregulation of genes 
with antiapoptotic, pro-metastastic, proliferative and invasive properties.  Due to its 
protumorigenic properties, NF-κB is often constitutively active in cancer, in both the tumors 
themselves, and in the tumor microenvironment.  NF-κB also plays an important role in 
oncogenic transformation, the process by which a normal cell becomes tumorigenic.  
Oncogenes such as Ras and BCR-ABL require NF-κB for efficient transformation (Finco et 
al., 1997; Reuther et al., 1998) through the inhibition of apoptosis induced by events leading 
to transformation (Mayo et al., 1997). 
In tumor cells, NF-κB promotes key oncogenic factors, including proliferation, 
metastasis, and evasion of apoptosis.  Direct regulation of proliferative genes, such as cyclin 
D1, by NF-κB is known to promote proliferation.  Expression of antiapoptotic factors such as 
Bcl-xL and Bcl-2, and inactivation of proapoptotic factors such as Foxo3a promote survival 
of tumor cells.  Tumor progression is promoted through the expression of proangiogenic 
genes VEGF, and prometastastic genes MMP-2 and MMP-9 (Bassères and Baldwin, 2006).  
NF-κB is active in cancers of many different organs, including breast, prostate, lung, 
pancreas, colon, brain, and in hematopoietic tumors including chronic myeloid leukemia, 
acute lymphoblastic leukemia, acute myeloid leukemia, and lymphoma (Bassères and 
Baldwin, 2006; Baldwin, 2001).  In the microenvironment, immune cells are known to 
exhibit activate NF-κB to increase production and excretion of proinflammatory cytokines, 
such as IL-6, to activate protumorigenic pathways and to block antitumor 
immunosurveillance.  In colitis-associated cancer, deletion of IKKβ inhibited transcription of 
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proinflammatory cytokines and reduced tumor formation in vivo (Greten et al., 2004).  
Breast epithelial cells transformed with mutant PI3K display activation of NF-κB and 
upregulate inflammatory cytokines.  Conditioned media experiments show that these 
cytokines are sufficient to activate STAT3 in both monocytes and normal epithelial cells, 
mainly through an IL-6-dependent manner (Hutti et al., 2012). 
 Due to the role of NF-κB in tumorigenesis, NF-κB is an attractive target for novel 
therapeutics in cancer.  Several IKKβ inhibitors are available to determine the efficacy of 
IKK/NF-κB inhibition in various types of cancer.  For example, treatment of lung tumor cells 
ex vivo with an IKKβ inhibitor reduces NF-κB activation {Basseres:2010ks}, and treatment 
of animals with mutant Kras-driven lung tumors resulted in tumor regression and prolonged 
survival (Xue et al., 2011).  However, IKKβ inhibition also leads to lymphocyte toxicity 
(Nagashima et al., 2006) and granulocytosis (Greten et al., 2007) in healthy animals.  Further 
studies are required to determine the effects of IKKβ inhibition in other in vivo cancer 
models, and if the benefits out weigh the side effects. 
 
1.3 Hematopoiesis 
            Hematopoiesis is a tightly regulated process that results in the production of blood 
cells.  Hematopoietic stem cells (HSC) maintain hematopoiesis through self-renewal and the 
ability to differentiate into all blood cell types.  Hematopoiesis is an ongoing process, as the 
life of most differentiated hematopoietic effector cells is very short.  These cells are replaced 
constantly following a well-defined sequence of events.  Adult hematopoiesis takes place in 
the bone marrow, where HSCs interact with the niche to maintain steady-state hematopoietic 
output through the regulation of self-renewal and differentiation. 
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            The principle characteristics of stem cells include the ability to self-renew and to 
differentiate into a variety of cell types.  Self-renewal is the process by which cells can self-
perpetuate through numerous cycles of cell division while maintaining an undifferentiated 
state (Morrison et al., 1995; Bryder et al., 2006).  HSCs can self-renew and support 
hematopoiesis throughout the lifetime of the recipient.  Self-renewal is a key aspect in 
radioprotection of lethally irradiated animals transplanted with HSCs.  Another key aspect of 
radioprotection is the ability to reconstitute required hematopoietic cells through 
differentiation.  HSCs are multipotent, defined by their ability to differentiate into cells of 
both the myeloid and lymphoid lineages, and can reconstitute all hematopoietic lineages in 
lethally irradiated transplant recipients (Morrison et al., 1995; Bryder et al., 2006). 
            HSCs are a rare population, comprising up to 0.05% of cells in the bone marrow of 
adult mice.  Several surface markers for the isolation and analysis of HSCs have been 
described over the years.  HSCs are defined using a variety of markers; however HSCs are 
lineage negative, lacking surface markers expressed on lineage restricted cells (B220, B cells; 
CD3, T cells; Gr-1, myeloid cells; Ter-119, erythrocytes; CD11b, myeloid cells).  Most long-
term HSC activity resides in the lineage negative, c-kit/CD117+, Sca-1+ fraction of bone 
marrow cells (Bryder et al., 2006).  Although enriched greatly when compared to whole bone 
marrow, the majority of the cells in this fraction, defined as the hematopoietic stem and 
progenitor cell (HSPC) fraction, are multipotent progenitors.  These cells can be further 
enriched using markers such as CD34, Flk2/Flt-3, and CD150/CD48 (SLAM) (Bryder et al., 
2006).  All HSCs are negative for Flk2/Flt-3 (Christensen and Weissman, 2001).  Long-term 
hematopoietic stem cells, which are capable of self-renewing over the lifetime of an animal, 
are CD34- and CD150+, while short-term HSCs are CD34+ (Bryder et al., 2006). 
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            HSCs first differentiate into multipotent progenitors (MPP), which have low self-
renewal capacity, but retain multipotency.  MPPs can differentiate into all hematopoietic cell 
types, and are positive for Flk2/Flt-3 expression (Boyer et al., 2011). These cells can then 
differentiate into common lymphoid (CLP) or common myeloid (CMP) progenitors.  CLPs 
can differentiate further into pro-lymphocytes, while CMPs can become either 
megakaryocyte/erythrocyte progenitors (MEP), which give rise to erythrocytes and platelets, 
or granulocyte/monocyte progenitors (GMP), which give rise to granulocytes and 
macrophages (Figure 2).  As the cell differentiate, they gain the capacity to proliferate and 
lose the ability to self-renew (Bryder et al., 2006). 
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Figure 1.2.  Model of hematopoietic development hierarchy. 
Adapted from  “Hematopoietic  Stem  Cells:  The  Paradigmatic  Tissue-Specific 
Stem Cell”  by  D.  Bryder,  D.J.  Rossi,  and  I.L.Weissman, 2006, The American 
Journal of Pathology, 169, p.339. Copyright 2006 by American Society of 
Investigative Pathology. 
Adapted with permission. 
 
             HSCs remain in a quiescent state in the bone marrow, and divide only once 
every 30-60 days (Passegué et al., 2005; Wilson and Trumpp, 2006).  Maintenance 
and fate of HSCs is thought to depend on the microenvironment, known as the stem-
cell niche.  Particular cytokines are thought to maintain stem cell quiescence (Wilson 
and Trumpp, 2006), while other contribute to the fate of differentiating cells (Robb, 
2007).  An important aspect of the niche is the ability to support non-differentiating 
and differentiating HSCs simultaneously.  It is currently unclear how this niche is 
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segregated to support these functions, and is an ongoing area of research.  Recently, 
mesenchymal cells (MSC) have been implicated as players in stem cell niche.  
Stromal MSCs express transcripts of HSC maintenance factors, including CXCL12 
and stem cell factor (SCF).  Deletion of niche-associated MSCs results in 
mobilization of approximately 50% of HSCs to the spleen, and greatly reduced 
homing of transplanted HSCs to the niche in recipients lacking MSCs (Ehninger and 
Trumpp, 2011). 
            MSCs can give rise to osteoblasts, which line the bones at the endosteum, the 
first location proposed as the HSC niche.  HSCs have been identified at the 
endosteum by imaging, and cells from this region display increased reconstitution 
ability.  Depletion of osteoblasts also results in the mobilization of HSCs to the 
spleen.  Osteoblasts are known to produce factors important for HSC retention, 
including CXCL12 and SCF, comparable to MCSs (Ehninger and Trumpp, 2011).  
Macrophages also play an important role in regulating HSCs in the niche.  Loss of 
macrophages results in the mobilization of HSCs to the spleen, and causes a decrease 
in the expression of HSC maintenance factors in MSCs (Ehninger and Trumpp, 
2011).  Further work to determine how the niche is organized, what factors influence 
cell fate, and how these factors are altered in abnormal hematopoiesis is likely 
ongoing. 
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1.4  Mouse models of NF-κB deletion 
            Deletion of NF-κB subunits and upstream regulators in vivo has effects on 
development and survival of various cell types.  Deletion of the NF-κB subunit p65, 
or p65 and c-rel, as well as the deletion of IKKβ result in liver apoptosis induced by 
TNFα, ultimately leading to embryonic lethality (Beg and Baltimore, 1996; 
Grossmann et al., 1999; Li et al., 1999).  Reconstitution of lethally irradiated 
recipients with p65-/- fetal liver cells display normal hematopoietic development, but 
have defects in lymphocyte proliferation (Grossmann et al., 1999) and secondary 
lymphoid organs (Alcamo et al., 2002).  Animals reconstituted with p65-/- c-rel-/- 
fetal liver cells succumb to anemia and granulocytosis, but display reconstitution of 
all hematopoietic lineages (Grossmann et al., 1999).  Other knockouts are viable, but 
have defects in immune response and inflammatory phenotypes.  Details of these 
defects are outlined in Table 1 and in section 1.4. 
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Table 1: Mouse models of NF-κB deletion 
Gene(s) Protein(s) Phenotype Source 
rela p65 (RelA) Embryonic lethal (Beg and Baltimore, 
1996) Liver apoptosis 
TNF sensitivity 
*Defects in lymphocyte 
proliferation 
(Grossmann et al., 
1999) 
c-rel c-Rel Impaired lymphocyte activation  (Köntgen et al., 1995; 
Grumont et al., 1998) 
relb RelB Inflammatory infiltrates of organs (Weih et al., 1995) 
Impaired antigen presentation by 
dendritic cells 
(Burkly et al., 1995) 
(Weih et al., 1995) 
Granulocytosis 
Skin inflammation (Freyschmidt et al., 
2007) 
nfkb1 p105 Abnormal B cell response (Sha et al., 1995) 
 
Resistance to arthritis (Campbell et al., 
2000) 
 
Neural degeneration (Lu et al., 2006) 
nfkb2 p100 Abnormal splenic architecture (Caamaño et al., 
1998) 
(Franzoso et al., 
1998) 
B cell reduction/impaired 
response 
Defective T-cell response 
nfkb2/RelB p52/RelB HSC defects 
Granulocyctosis 
Death 3-10 months post-natal 
(Zhao et al., 2012) 
nfkb1/relb p105/RelB Lethal at 3-4 weeks post-natal 
Organ inflammation 
(Weih et al., 1997) 
nfkb1/nfkb2 p105/p100 Growth retardation (Iotsova et al., 1997) 
(Franzoso et al., 
1997) 
Craniofacial abnormalities due to 
bone thickening 
Block in B cell development 
Block in osteoclast development 
Abnormal splenic architecture 
Impaired macrophage function 
nfkb1/c-rel p105/c-Rel Decreased humoral immunity (Pohl et al., 2002) 
Deregulated cell cycle of B and T 
cells 
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c-rel/rela c-
Rel/p65 
Embryonic lethal (Grossmann et al., 1999) 
Liver apoptosis 
Defective erythrocyte 
differentiation 
*Anemia 
*Granulocytosis 
ikba IκBα Lethal at neonatal day 7-10 (Beg et al., 1995) 
 
Inflammatory dermatitis (Klement et al., 1996) 
Granulocytosis 
ikkb IKKβ Embryonic lethal (Li et al., 1999) 
Liver apoptosis 
TNF sensitivity 
#Granulocytosis (Greten et al., 2007) 
#Splenomegaly 
ikka/ikkb IKKα/I
KKβ 
Embryonic lethal (Li et al., 2000) 
Liver apoptosis 
TNF sensitivity 
Neural defects 
ikkg IKKγ Embryonic lethal (Rudolph et al., 2000) 
 Liver apoptosis 
TNF sensitivity 
Skim inflammation and 
hyperkeratosis 
(Makris et al., 2000) 
*Phenotype in recipients reconstituted with fetal liver cells 
#Phenotype in a conditional deletion mutant 
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1.5 NF-κB in hematopoiesis 
The NF-κB family of transcription factors is involved in the expression of a variety of 
genes involved in inflammation, immune response, and survival (Bassères and Baldwin, 
2006).  Therefore, it is not surprising that NF-κB could play a role in hematopoietic cell fate 
and function.  Mouse models have been utilized to determine the effects of NF-κB pathway 
manipulation in lineage-restricted progenitors, while effects of NF-κB deletion in 
hematopoietic stem and early progenitors has largely gone untouched. 
Little evidence exists describing a requirement for classical NF-κB signaling in early 
hematopoiesis.  Mice engrafted with fetal liver cells from p65-/- animals develop all lineages 
of hematopoietic cells and appear to be relatively normal (Alcamo et al., 2002; Igarashi et al., 
2006).  However, animals engrafted with c-rel-/- p65-/- fetal liver cells display decreased 
engraftment efficiency.  Defects in short-term reconstitution have also been suggested, 
although death of recipients is more likely induced by severe anemia and granulocytosis than 
engraftment failure (Grossmann et al., 1999). 
Recent evidence has shown involvement of alternative NF-κB signaling in 
hematopoiesis.  The subunits p52 and RelB are shown to be important for self-renewal of 
hematopoietic stem cells.  Animals null of RelB/p52 show a severe decrease in the number of 
functional HSCs in their bone marrow.  Although the number of HSPCs increased by 
approximately 2-fold in p52/RelB-/- mice, the number of long-term stem cells was decreased 
by 5-fold.  Null HSCs show very poor engraftment efficiency in transplant recipients.  Of the 
recipients that did engraft, survival was at least 16 weeks and showed reconstitution of 
primarily the myeloid lineages of hematopoietic cells.  Due to the model system, in which 
p52 and RelB were knocked out in all cells, effects on the microenvironment were also 
 14 
studied.  The data indicate that RelB/p52 activation is important for the maintenance of 
stromal cells in the bone marrow to maintain HSC quiescence (Zhao et al., 2012). 
NF-κB is an important regulator of myeloid cell development.  Hematopoietic 
conditional IKKβ deletion animals develop granulocytosis and splenomegaly, and are more 
susceptible to toxic shock induced by exposure to LPS (Greten et al., 2004).  Animals treated 
with ML120B, an IKKβ inhibitor, also develop mild granulocytosis (Nagashima et al., 2006).  
Granulocytosis in these animals has been attributed to a cytokine feedback loop, where 
TNFα-dependent apoptosis of myeloid progenitors leads to the release of IL-1β, which 
promotes the Th17 polarization of peripheral CD4+ T cells.  These cells release IL-17, 
inducing the production of GM-CSF and subsequent proliferation of myeloid cells (Mankan 
et al., 2011).  The role of NF-κB in this feedback loop was not examined. 
Mice deficient for IκBα die at postnatal day 7-10 due to severe inflammatory 
dermatitis and granulocytosis.  These animals display an increase in CFU-GEMM, 
suggesting that NF-κB contributes to the differentiation of these lineages (Gerondakis et al., 
1999; Bottero et al., 2006).  Mice engrafted with fetal liver cells from c-rel-/- rela-/- animals 
also display deregulated granulocyte proliferation (Grossmann et al., 1999).  Conditional 
deletion of TAK1, an upstream activator of NF-κB, also results in granulocytosis and 
splenomegaly (Alagbala Ajibade et al., 2012).  Taken together, these studies suggest that NF-
κB is an important regulator of myeloid cell development.  
NF-κB activity is also required for the differentiation and function of lymphocytes.  A 
great deal of work has been performed to determine the importance of NF-κB subunits at 
various stages of B and T cell development.  Single and double NF-κB subunit knockouts 
show defects in most stages of B cell development and ability to mount a humoral immune 
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response upon antigen challenge (Gerondakis et al., 1999).  T cells in animals lacking 
various NF-κB subunits display decreased proliferation, defects in differentiation at later 
stages, and a controversial role in cell survival during negative selection (Bottero et al., 
2006).  Defects in lymphocyte development and function due to loss of specific subunits are 
outlined in Table 1. 
Taken together, data collected from various genetic model of NF-κB deletion show 
that each subunit plays an important role in development or immune response.  The most 
severe phenotypes, including embryonic lethality, and notable defects in immune response 
occur in animals lacking p65/RelA and RelB, two of the three subunits that possess 
transactivation domains, and are required to drive transcription of target genes involved in 
survival and immune response.  Interestingly, loss of c-rel does not result in a severe 
phenotype, which may be due to compensation by other subunits.  These data indicate that 
therapeutics involving the inhibition of NF-κB should be used with caution. 
 
1.6 Chronic myeloid leukemia 
            Chronic myeloid leukemia is a malignant clonal disorder of hematopoietic stem cells 
that results in increased and deregulated growth of myeloid cells.  About 95% of CML cases 
arise from the formation of the Philadelphia (Ph) chromosome, a product of chromosomal 
translocation that brings together the c-abl gene on chromosome 9 and the bcr gene on 
chromosome 22.  This translocation results in the creation of the BCR-ABL fusion protein, 
which is a constitutively active tyrosine kinase (Sawyers, 1999).  As a consequence of 
increased tyrosine kinase activity, BCR-ABL can phosphorylate a variety of substrates 
including Grb2, Crkl and Shc, and activate multiple signaling cascades, such as the Ras 
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pathway, PI3K/Akt and Stat5 (Diaz-Blanco et al., 2007), affecting the growth and 
differentiation of cells. 
            CML is characterized by distinct clinical phases.  During the chronic phase of the 
disease, mature granulocytes are still produced, but patients have an increased number of 
myeloid progenitor cells in the peripheral blood.  As the disease progresses, patients enter 
accelerated phase followed by blast crisis, where hematopoietic differentiation is inhibited 
and immature blasts accumulate in the bone marrow, spilling into the circulation (Melo and 
Barnes, 2007).  Current treatment options for CML include the BCR-ABL tyrosine kinase 
inhibitor, imatinib, as well as second-generation inhibitors such as dasatinib.  These 
inhibitors work by blocking the binding of ATP to the BCR-ABL tyrosine kinase, inhibiting 
its ability to phosphorylate downstream protein targets.  While imatinib results in complete 
hematologic and cytogenetic responses in 98% and 87% of patients, respectively (Druker et 
al., 2006), only 4% of patients entered complete molecular remission, defined by the 
disappearance of BCR-ABL transcripts using quantitative PCR (Hughes et al., 2003).  
Patients must continue imatinib treatment indefinitely to keep the disease in remission.  
However, the effectiveness of imatinib decreases greatly in patients in the accelerated or 
blast-crisis phases of the disease (Druker et al., 2006). 
 
1.6.1 Drug resistance in chronic myeloid leukemia 
            The most widely studied and well-characterized mechanism of imatinib resistance is 
the development of point mutations in the tyrosine kinase domain of BCR-ABL.  These point 
mutations can result in conformations that are inaccessible to Imatinib or alter key residues 
necessary for imatinib binding (O'hare et al., 2007).  The development of second-generation 
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tyrosine kinase inhibitors, including dasatinib, have eluded most imatinib resistant mutations 
with the exception of the T315I mutation, which renders cells resistant to all available BCR-
ABL tyrosine kinase inhibitors.  Dasatinib is also only effective in approximately 50% of 
patients in accelerated phase, and 30% of patients in blast-crisis (Cortes et al., 2007).  This 
suggests that mechanisms beyond BCR-ABL point mutations can also lead to tyrosine kinase 
inhibitor resistance. 
            One such mutation is the overexpression and increased activity of the tyrosine kinase 
Lyn.  Lyn is a Src family kinase member present in myeloid and B cells.  It is essential in 
pre-B cell receptor-mediated NF-κB activation and B cell development (Saijo et al., 2003).  
However, in samples collected from imatinib resistant patients, Lyn remains phosphorylated 
and active even under increasing doses of imatinib.  Persistent activation of Lyn kinase is 
associated with BCR-ABL mutation negative, Imatinib-resistance in cell lines and patient 
samples (Donato et al., 2003).  Imatinib-resistant K562 cells, derived from a cell line isolated 
from a patient in blast crisis, have increased Lyn protein levels and activity and partially rely 
on Lyn for survival.  Cells isolated from imatinib-resistant patients also show increased 
activation of Lyn (Donato et al., 2003; Wu et al., 2008).  Upregulation of Lyn also occurs in 
lymphomas.  Plasmablastic lymphomas show increased Lyn activity.  Interestingly, 
lymphoma growth is attenuated by administration of an IKK inhibitor in mice.  Furthermore, 
inhibition of Lyn decreases NF-κB activity and proliferation in a lymphoma cell line 
(Prakash et al., 2005). 
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1.6.2 Leukemia stem cells 
            In CML and other cancers, a primitive population of cells, known as cancer stem 
cells, have escaped the normal control of self-renewal, resulting in the propagation of cancer 
(Kavalerchik et al., 2008).  Hematopoietic development in CML is organized into a hierarchy 
that resembles that of normal hematopoiesis.  The production of leukemic progeny is fueled 
by the presence of leukemic cells with self-renewing properties, known as leukemia stem 
cells (Ren, 2005).  These cells initiate the chronic phase of the disease as a result of 
acquisition of the Philadelphia chromosome.  However, BCR-ABL is not sufficient for the 
generation of leukemia stems cells involved in blastic transformation.  Mice that receive 
BCR-ABL-tranduced bone marrow cells aquire a myeloproliferative disorder that is similar 
to chronic phase CML, but rarely enter blast crisis (Daley et al., 1990; Pear et al., 1998).  
Other mutations may be necessary to facilitate leukemogenesis.  For example, 
overexpression of HOXA9 and MYC, inhibition of proapoptotic transcription factors like 
JunB and secondary chromosomal translocations such as NUP98-HOXA9 have been 
implicated in the transition to blast crisis (Ren, 2005; Jamieson, 2008). 
            CML stem cells have increased BCR-ABL kinase activity, even in the presence of 
imatinib.  In fact, human CML stem cells, defined as CD34+ CD38-, are resistant to tyrosine 
kinase inhibitors regardless of their mutation status (Copland et al., 2006).  Patients 
successfully treated with imatinib have residual BCR-ABL+ CD34+CD38- cells (Graham et 
al., 2002).  Elimination of CML stem cells in chronic phase by other available agents is also 
unsuccessful (Jamieson, 2008).  These data suggest that the CML stem cell population is a 
promising target for therapeutics. 
 
 19 
1.6.3 NF-κB in chronic myeloid leukemia 
            NF-κB is activated in many solid tumors (Bassères and Baldwin, 2006) and 
hematologic malignancies, including Ph+ acute lymphoblastic leukemia (ALL), acute 
myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid 
leukemia (CML) (Braun et al., 2006).  Our lab and others have previously demonstrated that 
BCR-ABL can activate NF-κB (Hamdane et al., 1997; Reuther et al., 1998).  This activation 
is partially dependent on Ras, and results in increased NF-κB nuclear translocation and 
enhanced transcriptional activity.  Expression of an IκBα super repressor, which cannot be 
inducibly phosphorylated and degraded, inhibits tumor formation in BCR-ABL-driven 
xenograft model (Reuther et al., 1998).   BCR-ABL-expressing myeloid cells were found to 
have increased MEK kinase 1 (MEKK1) activity, which acts upstream of JNK, ERK and NF-
κB.  Expression of a MEKK1 mutant reduced NF-κB activation and the transcription of anti-
apoptotic, NF-κB regulated genes (Nawata et al., 2003), indicating a role for MEKK1 in the 
activation of NF-κB downstream of BCR-ABL.  We and others have also shown that IKKβ 
inhibition in BCR-ABL-expressing cells induces cell death (Cilloni et al., 2006; Duncan et 
al., 2008; Lounnas et al., 2009).  Interestingly, Imatinib and/or Dasatinib resistant cells were 
equally susceptible to IKKβ inhibition (Duncan et al., 2008).  Together, these data show an 
important role for NF-κB in the survival and tumorigenicity of BCR-ABL-expressing cells. 
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1.7 Conclusions 
Drug resistance through mutations and upregulation of secondary signaling pathways, 
as well as the maintenance of leukemia stem cells, is an ongoing clinical problem in the 
treatment of patients with chronic myeloid leukemia.  Novel therapeutic targets that are able 
to target cells refractory to current therapies are needed.  NF-κB is a promising target for the 
treatment of CML in the clinic given that BCR-ABL-expressing cells require NF-κB activity 
for survival (Duncan et al., 2008; Cilloni et al., 2006).  Further experiments are required to 
determine the efficacy of IKKβ inhibition in an in vivo model of CML to account for 
potential issues due to cues from the microenvironment and drug metabolism.  Toxicity due 
to IKKβ inhibition is also a concern (Nagashima et al., 2006; Greten et al., 2007; Mankan et 
al., 2011).  More insight into the effects of long-term NF-κB inhibition on normal 
hematopoiesis is required to determine if the benefits out weight the costs of IKKβ inhibition 
if drug-resistant CML patients. 
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CHAPTER II 
IKKβ INHIBITION INDUCES CELL DEATH IN IMATINIB-RESISTANT 
AND T315I DASATINIB-RESISTANT BCR-ABL+ CELLS 
 
This chapter has been adapted from: Duncan EA*, Goetz CA* and Stein SJ* et al. IKKβ 
Inhibition Induces Cell Death in Imatinib-Resistant and T315I Dasatinib-Resistant BCR-
ABL+ Cells.  Molecular Cancer Therapeutics 2007. 7 (2): 391-397. 
*These authors contributed equally to this work. 
 
 
2.1 Abstract 
Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic stem 
cell compartment, and is driven by expression of the BCR-ABL fusion protein. Expression of 
BCR-ABL allows myeloid cells to grow in the absence of the growth factors IL-3 and GM-
CSF. The tyrosine kinase activity of BCR-ABL constitutively activates signaling pathways 
associated with Ras and its downstream effectors, and within the Jak/STAT pathway. 
Additionally, we previously reported that BCR-ABL activates the transcription factor NF-κB 
in a manner dependent on Ras and that inhibition of NF-κB by expression of a modified form 
of IκBα blocked BCR-ABL-driven tumor growth in a xenograft model. Here we show that a 
highly specific inhibitor of IKKβ, a key upstream regulator of the NF-κB pathway, induces 
growth suppression and death in cells expressing wild-type, imatinib-resistant, or the T315I 
imatinib/dasatinib-resistant forms of BCR-ABL. Cell cycle parameters were not affected by 
this compound. These data indicate that blockage of BCR-ABL-induced NF-κB activation 
via IKKβ inhibition represents a potential new approach for treatment of imatinib- or 
dasatinib-resistant forms of CML. 
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2.2 Introduction 
The t(9;22)(q34;q11) chromosomal translocation is the most frequent cytogenetic 
abnormality found in human leukemias where it can be detected in approximately 95% of 
patients with chronic myelogenous leukemia (CML) and in 30 to 40% of pre-B and acute 
lymphoblastic leukemia (ALL) (Kurzrock et al., 1998; Gleissner et al., 2002; Westbrook et 
al., 1992). This translocation results in the fusion of the BCR and ABL genes, leading to the 
expression of a BCR-ABL fusion protein with constitutively active ABL tyrosine kinase 
activity (Kurzrock et al., 1998; Rosenberg et al., 1988). BCR-ABL-induced signaling is 
known to activate Ras-dependent signaling, PI3K/Akt, and the Jak/STAT pathway 
(Deininger et al., 2000). Additionally, BCR-ABL activates the transcription factor NF-κB, at 
least partly in a manner dependent on Ras (Reuther et al., 1998).  Suppression of NF-κB 
activation by expression of the so-called super-repressor form of IκBα blocked BCR-ABL-
dependent xenograft tumor formation (Reuther et al., 1998).  Others have also observed that 
NF-κB is activated by BCR-ABL in manner dependent on Ras.  Furthermore, that study 
reported constitutive NF-κB DNA binding activity in CML blasts (Kirchner et al., 2003). 
The NF-κB/Rel family of transcription factors is comprised of homo- and 
heterodimers of p65/RelA, c-Rel, RelB, NF-κB1/p50 or NF-κB/p52.  The IkB family of 
inhibitory proteins, which functions to promote cytoplasmic accumulation of NF-kB dimers 
and to prevent DNA binding activity, negatively regulates NF-kB. NF-κB is activated 
downstream of signals elicited by inflammatory cytokines such as TNF and by bacterial 
products such as LPS. The primary mechanism for activation of NF-κB involves the 
activation of the IκB kinase (IKK), which induces the phosphorylation, and ubiquitination of 
IκB. This leads to the degradation of the inhibitory IκB proteins and the subsequent 
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accumulation of NF-κB dimers in the nucleus. IKK is comprised of two catalytic subunits, 
IKKα and IKKβ, and a regulatory subunit, IKKγ/NEMO.  IKKβ is described as the dominant 
catalytic subunit in the classical pathway downstream of TNF, and IKKα is involved in a 
pathway associated with activation of the so-called alternative pathway, which activates 
p52/RelB heterodimers (Hayden and Ghosh, 2004).  NF-κB is strongly associated with 
oncogenesis where it is often important for cell proliferation, suppression of apoptosis, and 
invasion/metastasis (Basseres and Baldwin, 2006; Karin, 2006).  NF-κ is activated in several 
hematologic malignancies, including CML (see above), acute myelogenous leukemia (AML), 
acute lymphoblastic leukemia, and Hodgkins disease (Guzman et al., 2001; Bueso-Ramos et 
al., 2004; Baumgartner et al., 2002; Kordes et al., 2000; Mathas et al., 2005). Recently 
inhibitors of IKKβ have been used to suppress growth of AML cells (Frelin et al., 2005) and 
a subset of diffuse large B-cell lymphoma (Lam et al., 2005). 
The hypothesis that CML can be treated by selective inhibition of BCR-ABL has now 
been demonstrated by the generation of Abl tyrosine kinase inhibitors with positive results in 
clinical trials of these compounds (Druker et al., 2001).  Phase 2 studies on the use of 
imatinib for the treatment of chronic and advanced stage CML have demonstrated dramatic 
responses, with more than 90% of patients with interferon-resistant chronic stage CML 
achieving a complete hematologic response.  Furthermore, approximately 75% of patients 
with newly diagnosed chronic phase disease achieve cytogenetic remission (Druker et al., 
2003; Kantarjian et al., 2002; O’Brien et al., 2003). However, most of the patients in blast 
crisis who initially respond to imatinib therapy ultimately relapse with disease that is 
resistant to imatinib. Resistance to imatinib in CML patients is caused primarily by point 
mutations in the kinase domain of BCR-ABL, which impair drug binding (Shah et al., 2002; 
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Nardi et al., 2004).  Dasatinib, a second-generation Abl inhibitor, is effective for most 
Imatinib-resistant CML (Shah et al., 2004; Talpaz et al., 2006).  However, dasatinib 
resistance is generated from mutations occurring directly in the drug-binding site on Abl 
(Azam et al., 2003).  One of these mutations, T315I, generates resistance to imatinib, 
dasatinib, and nilotinib (Talpaz et al., 2006; Weisberg et al., 2005).  Imatinib resistance can 
also be generated by poorly described mechanisms.  In this regard, IKK inhibition blocked 
growth of imatinib-resistant cells (K562 and KCL) that do not express BCR-ABL point 
mutants (Cilloni et al., 2006). 
Here we have tested whether inhibition of the NF-κB/IKK pathway is effective at 
suppressing growth of cells expressing point mutants in BCR-ABL that lead to imatinib or 
dasatinib resistance. Our results show that a highly selective IKKβ inhibitor, shown to be 
effective at blocking inflammatory progression in vivo (compound A [hereafter CpA]; 
Ziegelbauer et al., 2005), strongly suppresses growth/viability of cells expressing either wild-
type or mutant versions of BCR-ABL, including the dasatinib resistant T315I mutation. 
Experimental results suggest that the involvement of NF-κB/IKK downstream of BCR-ABL 
is distinct from the NF-κB activation response shown to be associated with WeHi media 
containing IL-3.  Overall, the data indicate that inhibition of IKKβ represents a therapeutic 
strategy for tyrosine kinase inhibitor-resistant BCR-ABL-expressing CML as well as in acute 
leukemias that express BCR-ABL. 
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2.3 Materials and Methods 
Cells and Reagents. Ba/F3 cell lines expressing BCR-ABL mutants were developed in the 
Sawyers lab (Skaggs et al., 2006).  Ba/F3 and 32D parental cells were maintained in RPMI 
with 10% FBS, 10 % conditioned WeHi media (as a source of IL-3), 100 µg/ml penicillin 
and 100 µg/ml streptomycin  (Sigma Chemical Co.).  Ba/F3 and 32D cells expressing BCR-
ABL oncoproteins (see Reuther et al., 1998; gift of Dr. A.M. Pendergast) were maintained 
without conditioned WeHi media.  All cell lines were grown at 5% CO2, 37 °C. Antibodies 
for c-abl and cleaved Caspase-3 were obtained from Cell Signaling.  Antibodies to 
proliferating cell nuclear antigen (PCNA) and β-Tubulin were obtained from Santa Cruz. 
Cell growth/viability.  Cell viability after treatment was measured by spectrophotometric 
monitoring of MTS reduction utilizing the CytoquantAQ assay system (Promega).  After 
optimization of cell number an equal number of cells were seeded in a 96-well plate.  
Inhibitors or DMSO (as indicated in the figures) was added to each well and the cells were 
incubated at 37oC overnight.  20 µl of CytoquantAQ reagent was added to each well, 
including the blank wells, and the mixture was incubated for 1 hour at 37oC.  Absorbance 
was read at 490nm. 
Stimulation of Ba/F3 and 32D cells for flow cytometry.  0.5 x 106 cells were seeded in 10 
mL of growth media and treated with DMSO, imatinib, dasatinab, the IKKβ inhibitor 
compound A, or compound B (less active), or compound C (an inactive structural analog of 
compound A) 24 hours at concentrations indicated in the figures.  The cells were processed 
for flow cytometry as described below. 
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Apoptosis Assay.  Apoptosis and cell death were assessed by staining with Propidium Iodide 
(BD Biosciences) and APC-labeled Annexin V (BD Biosciences) according to the 
manufacturer’s protocol.  After stimulation with the inhibitors described above, the cells 
were washed twice in ice-cold 1x PBS.  They were then resuspended in 100 µl of 1x Binding 
buffer (BD Biosciences) and 2.5 µl of Propidium Iodide (PI) and Annexin V (AV) were 
added to the cells.  The cells were incubated at room temperature for 15 minutes, and 250 µl 
of 1x Binding buffer was subsequently added to stop the reaction.  The cells were analyzed 
immediately on a CyAn flow cytometer (Dako).  Cell death was characterized by the level of 
AV and PI staining where apoptotic cells are AV+, PI- and dead cells are AV+, PI+.   
Cell Cycle Analysis.  Cell cycle analysis was performed by staining with Propidium Iodide 
(BD Biosciences) according to the manufacturer’s protocol.  After stimulation for 24 hrs with 
the inhibitors described above, 32D and 32D/p185 cells were fixed in ice-cold 70% ethanol 
(added dropwise while vortexing) for 1 hour at 4°C.  The cells were then centrifuged (400 x 
g for 5 minutes) and washed once in staining buffer (2% FBS, 1xPBS).  After centrifugation, 
the cells were resuspended in100 µl staining buffer.  The cells were then treated with RNAse 
A (Sigma; 1 µl/sample) and incubated for 30 minutes at 37°C.  After RNase A incubation, 
the cells were stained for 30 minutes at room temperature (protected from light) with 10 µg 
PI in a final volume of 0.5 ml staining buffer.  The samples were then analyzed by flow 
cytometry at a flow rate <400 events/second.  The percentage of cells in G0-G1, S phase, and 
G2-M were calculated using ModFit (Verity Software House). 
Western Blot Analysis.  Western blot analysis was performed after fractionation of cellular 
contents into cytosolic and nuclear fractions or whole cell lysis, as indicated. Proteins (20 
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µg/lane) from the extracts were separated using NuPAGE Novex 4-12% Bis Tris gels 
(Invitrogen) followed by immunoblotting with antibodies as indicated. 
 
2.4 Results 
IKKβ inhibition decreases IκBα  phosphorylation levels in BCR-ABL expressing cells. 
 Ba/F3 cells stably expressing p210 BCR-ABL as well as drug-resistant variants, and 
32D cells expressing p185 BCR-ABL, were developed previously (see Reuther et al, 1998; 
Skaggs et al., 2006). Immunoblotting confirms the expression of BCR-ABL in the different 
cell lines (Figure 2.1A).  As a measure of NF-κB activation downstream of BCR-ABL, we 
analyzed phosphorylation of IκBα at ser32/36.  Notably, phosphorylation of IκBα is 
significantly higher in 32D/p185 cells as compared to the parental 32D cells (Figure 2.1B), 
consistent with reports showing that BCR-ABL induces NF-κB activation (Reuther at al., 
1998; Kirchner et al., 2003).  Additionally, this result demonstrates that IKK is activated 
downstream of BCR-ABL since IKK phosphorylates IκBα at serines 32 and 36 (Hayden and 
Ghosh, 2004).  To analyze the effects of imatinib and a recently described inhibitor of IKKβ 
(Cp A) on IκBα phosphorylation, 32D cells and those expressing the p185 form of BCR-
ABL were treated with DMSO, imatinib, the IKK inhibitor CpA, or a structurally inactive 
form of compound A (CpC).  Treatment with imatinib partly reduced while CpA, but not 
CpC, significantly reduced IκBα phosphorylation in 32D/p185 cells (Figure 2.1B) indicating 
that BCR-ABL activates IKK, which induces IκBα phosphorylation.  Additionally, these 
results show that CpA is an effective inhibitor of IKK/NF-κB activation downstream of 
BCR-ABL-induced signaling. 
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BCR-ABL expression induces susceptibility to IKKβ  inhibition. 
Previously we had shown that BCR-ABL induces strong NF-κB-dependent 
transcriptional activity and that inhibition of NF-κB via IκBα expression blocked tumor 
growth driven by BCR-ABL in a xenograft model (Reuther et al., 1998).  Based on these 
results, we asked whether IKKβ inhibitor CpA (1 µM) would affect the growth/viability of 
32D cells or 32D/p185 cells as measured in an MTT assay. The effects of IKKβ inhibitor 
CpA were compared to the effects of imatinib (1 µM) and dasatinib (5 nM), both with well-
established activity against BCR-ABL-expressing cells. Additionally, we included an IKKβ 
inhibitor (CpB) with weaker activity than IKKβ inhibitor CpA and an inactive, related 
compound (CpC).  The results (Figure 2.2) demonstrate that IKKβ inhibitor CpA, at a dose 
of 1 µM, is effective at suppressing cell growth/viability of 32D/p185 cells with minimal 
effects on the parental 32D cells. As expected, imatinib and dasatinib each reduced cell 
growth/viability of 32D/p185 cells. IKKβ inhibitor CpB reduced viability of 32D/p185 cells 
but less effectively than IKKβ inhibitor CpA, consistent with its lower effectiveness as an 
IKKβ inhibitor. The inactive IKKβ inhibitor compound did not affect cell growth/viability. 
Similar results were observed with the proB Ba/F3 cell line expressing p210 BCR-ABL 
(Figure 2.2B), although the IKKβ inhibitor reduced cell growth/viability of the parental pro-
B cells presumably indicating the involvement of NF-κB at some level in control of 
proliferation or survival of these cells. Titration of IKKβ inhibitor CpA demonstrated 
observable cell growth/viability effects around 100 nM, with an approximate 10-folder 
stronger effect at that concentration, and at 1 µM and 10µM, in 32D/p185 cells as compared 
to the 32D parental cells (Fig. 2.2C). 
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WEHI media does not overcome the inhibitory effect of IKKβ  blockade on 32D/p185 cell 
viability. 
Expression of BCR-ABL generates growth factor-independent growth of 32D 
myeloid cells (Deininger et al., 2000).  Addition of WEHI media (as a source of IL-3) to 
BCR-ABL-expressing cells overcomes the inhibitory block on cell viability induced by 
imatinib or dasatinib, essentially recreating a myeloid cell without BCR-ABL activity (Figure 
2.3A). However, IKKβ inhibitor-treated 32D/p185 cells cannot be rescued with WEHI media 
(Figure 2.3A). 
 
WEHI-controlled growth/survival does not require IKKβ  in myeloid cells where BCR-ABL 
is inactive. 
We then asked if 32D/p185 cells exposed to IKKβ inhibitor could be rescued with 
WEHI media, or with imatinib and WEHI media.  32D/p185 cells were incubated in the 
presence or absence of WEHI and/or imatinib for 24 hours.  Subsequently, IKKβ inhibitor 
Cp A (or C) was added for an additional 20 hours and cell viability was assessed.  The results 
of this experiment (Figure 2.3B) reveal that WEHI alone does not rescue the cells when IKK 
is inhibited, consistent with the results shown in Figure 3A. However, WEHI media plus 
imatinib rescues cell viability in 32D/p185 cells exposed to IKKβ inhibitor. This result shows 
that growth factor-induced growth/survival of 32D cells (where BCR-ABL is inactivated or 
not expressed) does not require IKKβ activity.  
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IKKβ  inhibition induces cell death in BCR-ABL expressing cells but does not affect cell 
cycle parameters. 
To analyze effects on 32D/p185 cell proliferation/viability induced by IKKβ 
inhibition, cells were treated with imatinib, dasatinib, or IKKβ inhibitor CpA (or inactive 
CpC) and were then assessed for cell death by staining with Annexin V (AV) and propidium 
iodide (PI).  The parental 32D cells exhibited no induction of apoptosis (AV+, PI-) with the 
various drug treatments.  However, a measurable, but relatively modest level early apoptosis 
was induced in the 32D/p185 BCR-ABL-expressing cells with tyrosine kinase inhibitors or 
with IKKβ inhibitor CpA (Figure 2.4A).  These results are consistent with known effects of 
BCR-ABL on blocking apoptosis in the transformation process (Kuroda et al., 2006). The 
inactive IKKβ inhibitor (CpC) exhibited no effects on apoptosis and showed essentially the 
same profile as DMSO treatment.  Correspondingly, the drug treatments that induced 
apoptosis also exhibited an increase in late apoptosis/necrosis (AV+, PI+).  In order to further 
examine an apoptotic response, immunoblotting was carried out to examine the level of 
cleaved caspase-3 in these cells follow inhibitor treatment.  Figure 3.4B shows that 32D/p185 
cells treated with imatinib, dasatinib, or IKKβ inhibitor exhibit increased levels of cleaved 
caspase-3 relative to the DMSO control.  This result suggests that the increased cell death 
observed in these cells upon drug treatment is mediated at least partly via apoptosis.  We note 
that IKKβ inhibition induces less early apoptosis at the 24 hr time point as compared to 
BCR-ABL inhibition, but relatively equivalent levels of overall cell death (AV+, PI+). 
Although there are elevated levels of apoptosis/cell death present in 32D/p185 cells treated 
with the drugs listed above, it is also possible that these drugs are exhibiting effects via a cell 
cycle block.  Therefore, cell cycle analysis was performed.  It was observed that 32D/p185 
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cells exhibit higher levels of G2-M and S-phase compartments as compared to parental 32D 
cells (Figure 2.5).  Experiments revealed that treatment with imatinib or dasatinib inhibits 
cell cycle progression in 32D/p185 cells, with enhanced G0-G1 accumulation and reduced 
numbers in S phase as compared to DMSO control. Treatment with IKKβ inhibitor CpA, or 
with inactive CpC, did not significantly alter cell-cycle parameters.  Importantly it was 
shown that cell cycle progression is not abrogated in 32D cells treated with these compounds 
(see Figure 2.5).  Overall, these studies indicate that IKKβ inhibition of BCR-ABL-
expressing myeloid cells induces a cell death response that can be partly attributed to 
apoptosis, but does not induce a cell-cycle block in a specific cell-cycle compartment.  Future 
studies will be required to determine if overall cell growth is blocked by IKKβ inhibition and 
whether non-apoptotic forms of cell death contribute to the IKKβ inhibition response in 
BCR-ABL+ cells. 
 
IKKβ  inhibition blocks viability in cells expressing wild-type, imatinib resistant, or the 
T315I-dasatinib resistant forms of BCR-ABL. 
Point mutations in the kinase domain of BCR-ABL produce resistance to imatinib and 
promote oncogenicity (22-27). We analyzed Ba/F3 cells expressing wild-type p210 or 
variants that are either imatinib resistant (Y253F and E255V) or both imatinib and dasatinib 
resistant (T315I).  Cells were exposed to imatinib, dasatinib, IKKβ inhibitor (CpA), or the 
inactive structural variant of the IKKβ inhibitor compound (CpC). Consistent with 
experiments shown above (Figure 2.2), each of the inhibitors strongly reduced the viability of 
cells expressing wild-type BCR-ABL (Figure 2.6). As expected, cells expressing mutant 
variants of BCR-ABL (E255V, Y253H, and T315I) were variably resistant to imatinib, with 
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the T315I mutant exhibiting complete resistance to imatinib. Those cells expressing the 
T315I mutation were also resistant to growth inhibition by dasatinib (Figure 2.6), as 
expected. Interestingly, each of the mutant cell lines, including the T315I line, was 
susceptible to IKKβ inhibition. The inactive IKKβ inhibitor (CpC) in DMSO showed no 
inhibitory effects on any of the cells. These studies show that blocking NF-κB/IKK 
suppresses viability of cells expressing all forms of BCR-ABL, including wild-type and 
imatinib- and dasatinib-resistant variants, indicating that IKK/NF-κB is required for 
growth/survival of BCR-ABL+ cells.  
 
2.5 Discussion 
The dramatic success of targeting BCR-ABL in CML has been dampened by the 
emergence of imatinib and dasatinib resistant variants in the kinase domain. An alternative or 
adjuvant approach is to target essential downstream regulators of BCR-ABL. Here we have 
addressed the potential that inhibition of NF-κB and/or its upstream regulator IKK will 
function to block growth/viability of cells expressing wild-type BCR-ABL or imatinib- or 
dasatinib-resistant variants (Figure 2.1A).  The IKKβ inhibitor, compound A, works to block 
the phosphorylation of IκBα in myeloid cells expressing BCR-ABL (Figure 2.1B).  Our 
results show that IKKβ inhibition functions similarly to imatinib and to dasatinib in 
suppressing growth of myeloid or pro-B cells expressing wild-type BCR-ABL or imatinib- or 
dasatinib-resistant forms of BCR-ABL (Figure 2.2A and Figure 2.2B).  More over, 
IKKβ inhibition has a greater effect of cell viability of BCR-ABL-expressing cells than 
parental cells, even at high doses (Figure 2.2C). 
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IKKβ inhibitor-treated 32D/p185 cells cannot be rescued with IL-3-rich WEHI media 
(Figure 2.3A). This result suggests one of the following possibilities: (i) WEHI media/IL-3 
requires IKK/NF-κB to promote cell growth/survival, (ii) BCR-ABL-activated signaling 
where IKKβ is inhibited interferes with the ability of IL-3 to induce cell survival, or (iii) NF-
κB activity promoted by growth factor support which involves Stat5 (Nakamura et al., 2002) 
is not sufficient to replace the NF-κB/IKK activity suppressed by IKKβ inhibition in the 
BCR-ABL-expressing cells. This latter hypothesis may be explained by different forms of 
NF-κB activated by growth factors versus BCR-ABL, by different modifications to NF-κB in 
response to growth factors or to BCR-ABL expression leading to distinct gene responses, or 
by a function of IKK controlled by BCR-ABL that is not regulated by growth factors. 
The viability of BCR-ABL-expressing cells treated with compound A and then 
subsequently treated with imatinib was partially rescued (Figure 2.3B).  This result indicates 
that BCR-ABL requires IKKβ activity to promote cell viability.  When BCR-ABL is blocked 
by imatinib, the cells revert to a growth-factor-dependent status.  IL-3 does not require IKKβ 
to promote cell growth as shown by this assay.  Thus the effect of IKKβ inhibition on 
blocking rescue of growth/survival by exogenous growth factors is mediated through BCR-
ABL-controlled suppression of the growth factor response under these conditions and/or 
through inhibition of an IKK/NF-κB function in BCR-ABL+ cells that cannot be 
recapitulated by growth factors. 
Treatment of BCR-ABL cells with compound A results in the induction of apoptosis, 
as indicated by the cleavage of caspase 3 (Figure 2.4A and 2.4B), but does not impact cell 
cycle status (Figure 2.5).  These results indicate that NF-κB/IKK is essential for BCR-ABL-
induced cell survival.  Further studies are required to understand the effects of IKKβ 
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inhibition on BCR-ABL+ cells relative to growth and survival.  Interestingly, IKKβ 
inhibition results in loss of cell viability of cells expressing imatinib- and dasatinib-resistant 
BCR-ABL mutants, including the T315I mutation (Figure 2.6).  These data indicate the 
potential for the use of IKKβ inhibitors as stand-alone therapies for CML or in combination 
with existing therapies. The results also indicate that IKKβ inhibition may be therapeutic in 
imatinib- and dasatinib-resistant disease. 
 41 
 
Figure 2.1: IKKβ  inhibitor CpA blocks phosphorylation of IκBα in BCR-ABL-
expressing cells.  (A) Whole cell extracts were prepared from untreated Ba/F3 parental and 
BCR-ABL expressing cells (left), and 32D and 32D/p185 cells (right).  Immunoblotting was 
performed with an antibody to ABL. (B) Cytoplasmic extracts were prepared from 32D and 
32D/p185 BCR-ABL cells treated with vehicle (DMSO), 1 mM imatinib, 1 µM IKKβ 
inhibitor (CpA), or 1 µM inactive related compound (CpC).  As a control, 32D/p185 cells 
were treated with TNF (5 ng/ml). Immunoblot analysis of was carried out using an antibody 
that recognizes IκBα phosphorylated on ser32/36.  β-tubulin or actin antibodies were used to 
normalize loading. Data are representative of 3 experiments. 
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Figure 2.2: IKKβ  inhibition suppresses growth/viability of BCR-ABL+ cells.  (A) 32D 
cells or 32D cells expressing p185 BCR-ABL were incubated for 20 hours in the presence of 
1 µM IKKβ inhibitor (CpA), 1 µM CpB or C, imatinib (1 µM), dasatinib (5 nM) or vehicle 
(DMSO).  Cell viability was assessed by reduction of MTS.  (B) Ba/F3 cells and Ba/F3 cells 
expressing p210 BCR-ABL were treated as in A.  All data points represent mean of 
biological replicates. Error bars represent standard deviation between replicates.  Graphs are 
representative of experiments performed in triplicate.  (C) 32D (triangles) and 32D 
expressing p185 BCR-ABL (squares) were treated with varying concentrations (as shown) of 
IKKβ inhibitor CpA for 20 hr and cell viability was measured as in A. 
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Figure 2.3:  WeHi-conditioned media rescues BCR-ABL+ cell susceptibility to tyrosine 
kinase inhibitors but not to IKKβ  inhibition.  Inhibition of BCR-ABL kinase activity 
promotes rescue by WeHi media.  (A) 32D cells expressing p185 BCR-ABL cells were 
cultured in the presence and absence of WEHI-conditioned medium for 24 hrs.  The cells 
were subsequently incubated with 1 µM imatinib, 5 nM dasatinib, 1 µM CpA, or 1 µM CpC 
and cell growth/viability was assessed after 20 hrs of treatment as described in Figure 2 
legend.  Bars indicate average values from replicates and standard deviation is shown.  (B) 
32D cells expressing p185 BCR-ABL were cultured for 24 hours in the absence of WEHI-
conditioned medium, the presence of WEHI-conditioned media, or the presence of WEHI-
conditioned medium and Imatinib.  The cells were subsequently incubated with 1  µM CpA 
or CpC and cell viability was assessed after 20 hrs of treatment.  Bars indicate average values 
from biological replicates.  Error bars represent standard deviations.  The graph is 
representative of experiment performed in triplicate. 
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Figure 2.4.  BCR-ABL+ cells undergo cell death in response to tyrosine kinase 
inhibitors or IKKβ  inhibition.  (A) 32D and 32D/p185 cells were stimulated for 24 hours 
with either DMSO, imatinib, dasatinib, CpA, or CpC.  Cells were stained with Annexin V 
and Propidium Iodide (PI), and cell death was measured by flow cytometry.  Apoptotic cells 
are characterized as Annexin V+, PI- and dead cells are Annexin V+, PI+.   Error bars 
represent standard deviations.  Results are representative of 3 experiments.  (B) Whole cell 
extracts from the experiment in (A) were analyzed by immunoblotting for cleaved caspase-3. 
β-tubulin antibody is used to normalize loading.  The data are representative of 3 different 
experiments.  
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Figure 2.5.  BCR-ABL+ cells exhibit G0-G1 accumulation in response to Imatinib or 
Dasatinib treatment, but not IKKβ  inhibition.  32D and 32D-p185 cells were stimulated 
for 24 hours with DMSO, imatinib, dasatinib, CpA, or CpC.  Cells were fixed, treated with 
RNase A, and stained with Propidium Iodide.  Cell cycle progression was measured by flow 
cytometry.  The percentage of cells in G0-G1, S phase, and G2-M were calculated using 
ModFit.  Error bars represent standard deviations.  Results are representative of 3 
experiments.   
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Figure 2.6:  Cells expressing tyrosine kinase inhibitor resistant BCR-ABL mutants are 
susceptible to IKKβ  inhibition.  Ba/F3 cells expressing p210 BCR-ABL (WT, wild type) or 
kinase inhibitor resistant variants were treated with tyrosine kinase or IKKβ inhibitors then 
analyzed for viability.  Cells expressing p210 BCR-ABL WT (white), Y253H, E255V, and 
T315I were treated for 18 hours with DMSO, 1 µM imatinib, 1 µM CpA, or 5 nM dasatinib 
and cell viability was assessed by reduction of MTS.  Bars represent average values of 
triplicates. Error bars demonstrate standard deviation of replicates.  Results shown are 
representative of 3 experiments.  
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CHAPTER III 
NF-κB SUPPRESSES ROS LEVELS IN BCR-ABL+ CELLS TO PREVENT 
ACTIVATION OF JNK AND CELL DEATH 
 
This chapter has been adapted from: Stein SJ and Baldwin AS. NF-κB Suppresses ROS 
Levels in BCR-ABL+ Cells to Prevent Activation of JNK and Cell Death.  Oncogene 2011. 
30 (45): 4557-4566. 
 
 
3.1 Abstract 
Elevated levels of reactive oxygen species are found in most oncogenically 
transformed cells and are proposed to promote cellular transformation through mechanisms 
such as inhibition of phosphatases.  BCR-ABL, the oncoprotein associated with the majority 
of chronic myelogenous leukemias, induces accumulation of intracellular ROS causing 
enhanced signaling downstream of PI3K.  Previously we have shown that the transcription 
factor NF-κB is activated by BCR-ABL expression and is required for BCR-ABL-mediated 
cellular transformation. Inhibition of IKKβ and NF-κB leads to cell death through an 
unknown mechanism.  Here, we analyze the potential involvement of NF-κB in moderating 
BCR-ABL-induced ROS levels to protect from death in response to cell stress.  The data 
confirm that BCR-ABL promotes ROS levels and demonstrate that NF-κB prevents 
excessive ROS levels.  Inhibition of NF-κB leads to an increase in ROS levels and to cell 
death controlled through ROS-induced JNK activity.  The data demonstrate that one function 
for NF-κB in oncogenesis is the suppression of oncoprotein-induced ROS levels and that 
inhibition of NF-κB in some cancers, including CML, will increase ROS levels and promote 
cell death. 
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3.2 Introduction: 
 Chronic myeloid leukemia is a malignant clonal disorder of hematopoietic stem cells 
that results in increased and deregulated growth of myeloid cells (Sawyers, 1999).  
Approximately 95% of CML cases arise from the formation of the Philadelphia (Ph) 
chromosome, a product of a chromosomal translocation that brings together the c-abl gene on 
chromosome 9 and the bcr gene on chromosome 22.  This translocation results in the creation 
of the BCR-ABL fusion protein, which is a constitutively active tyrosine kinase (Sawyers, 
1999).  As a consequence of increased tyrosine kinase activity, BCR-ABL phosphorylates 
substrates including Grb2, Crkl and Shc, and activates signaling cascades, such as the Ras 
pathway, PI3K/Akt and Stat5, affecting the growth and differentiation of myeloid cells 
(Diaz-Blanco et al., 2007). 
 NF-κB is a transcription factor comprised of five family members: p65 (RelA), RelB, 
c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2).  These proteins share a conserved Rel 
homology domain, which controls DNA binding, dimerization and interaction with inhibitory 
IκB proteins (Bassères and Baldwin, 2006; Courtois and Gilmore, 2006).  NF-κB activation 
typically occurs through one of two distinct pathways.  In the classical pathway, the p50-
p65(RelA) heterodimer is activated by the IκB kinase (IKK) complex, which contains two 
catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ.  IKK phosphorylates 
IκBα, an inhibitory protein that normally sequesters p50-p65 in the cytoplasm, causing it to 
become ubiquitinated and subsequently degraded, allowing NF-κB to accumulate in the 
nucleus.  In the alternative pathway, IKKα homodimers are activated and subsequently 
phosphorylate p100.  This results in the proteolytic processing of p100 to p52 and allows 
p52-RelB dimers to translocate to the nucleus (Hayden and Ghosh, 2004).  Once in the 
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nucleus, NF-κB is known to regulate the expression of a variety of genes, including those 
encoding cytokines and cytokine receptors, inflammatory mediators, and antiapoptotic 
proteins (Bassères and Baldwin, 2006).   
 NF-κB is activated in many solid tumors (Basséres and Baldwin, 2006) and 
hematologic malignancies, including CML (Braun et al., 2006), where it provides 
proliferative and cell survival mechanisms. NF-κB is activated by BCR-ABL and is required 
for cellular transformation and tumor formation induced by this oncoprotein (Hamdane et al., 
1997; Reuther et al. 1998).  Inhibition of IKK in BCR-ABL-expressing cells induces death 
(Cilloni et al., 2006; Duncan et al., 2008).  Interestingly, Imatinib- and/or Dasatinib-resistant 
cells were shown to be susceptible to IKKβ inhibition (Duncan et al, 2008), suggesting a 
novel therapeutic option for CML.  However, the mechanism whereby IKKβ inhibition 
induces death of BCR-ABL-expressing cells has not been determined. 
c-Jun N-terminal kinase (JNK), also known as stress-activated protein kinase 
(SAPK), is a member of the MAPK family and is involved in the regulation of c-jun, a 
component of the AP-1 family of transcription factors (Leppä and Bohmann, 1999).  JNK is 
predominately activated by cellular stress mechanisms, including increased levels of reactive 
oxygen species (ROS), but can also be activated by other stimuli including cytokines and 
oncogenic transformation. JNK is actived by MAPKKs through the phosphorylation of 
threonine 183 and tyrosine 185.  JNK then phosphorylates c-Jun at serines 63 and 73 causing 
an increase in c-Jun transcriptional activity (Gupta et al., 1996).  c-Jun activity is implicated 
in cell transformation, proliferation and death downstream of JNK (Leppä and Bohmann, 
1999; Vogt, 2001).  Interestingly, both c-jun and JNK are required for transformation of 
hematopoietic cells by BCR-ABL (Raitano et al., 1995) as well as their survival after 
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transformation (Hess et al., 2002).  However, under stimuli that induce cell stress, JNK 
activation can lead to death (Shen and Liu, 2006; Dhanasekaran and Reddy, 2008). JNK 
becomes activated by stimuli in a constitutive manner through increased intracellular ROS 
and activates apoptotic and necrotic death pathways (Tang et al, 2002; Pham et al, 2004; 
Ventura et al., 2004; Kamata et al, 2005).   
It has been demonstrated that oncogenic transformation results in increased levels of 
intracellular ROS, which are used as secondary signaling molecules to increase proliferation 
and to promote the oncogenic potential of transformed cells (Pelicano et al., 2004; Benhar et 
al., 2002).  For example, oncogenic Ras leads to increased levels of ROS, which are 
important in oncogenic transformation and proliferation (Irani et al., 1997). Previous reports 
have shown that hematopoietic cell lines transformed with BCR-ABL have increased levels 
of intracellular ROS (Sattler et al, 2000; Kim et al, 2005; Naughton et al., 2009).  ROS 
promotes PI3K-induced signaling downstream of BCR-ABL by inhibiting phosphatases 
which normally limit signal transduction cascades (Naughton et al., 2009), thereby increasing 
tumorigenicity.  
Here we have explored the potential involvement of NF-κB in moderating 
intracellular ROS levels downstream of BCR-ABL.  The results indicate that NF-κB activity 
functions to suppress BCR-ABL-induced ROS levels.  Additionally, inhibition of IKK or 
NF-κB leads to enhanced ROS levels and elevated JNK activity to promote cell death.  The 
experiments reveal a key pro-oncogenic mechanism and demonstrate a mechanism whereby 
inhibition of NF-κB activity promotes cytotoxicity of certain cancer cells. 
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3.3 Materials and Methods 
 
Cell lines.  32D and Ba/F3 hematopoietic murine cells were maintain in RPMI 1640 medium 
(Gibco, Grand Island, NY) supplemented with 10% FBS and 10% Wehi-conditioned media 
as a source of IL-3.  32D and Ba/F3 cells stably expressing p185 or p210 BCR-ABL, 
respectively, were maintained in RPMI 1640 supplemented with 10% FBS.  293Ts were 
maintained in DMEM supplemented with 10% FBS. 
Chemicals.  2′,7′-Dichlorodihydrofluorescein Diacetate (DCF-DA; Calbiochem, Gibbstown, 
NJ) was dissolved in DMSO.  Catalse and n-acetyl-cysteine (Sigma, St. Louis, MO) were 
dissolved in culture media.  The pH of NAC was then adjusted to 7.2 and the stock was 
subsequently passed through a 0.2µm filter. Butylated hydroxyanisole (Sigma) was dissolved 
in ethanol.  Compound A, SP600125 (Sigma) and Z-VAD-FMK (Sigma) were dissolved in 
DMSO.  All stocks were diluted to working dilutions in culture media. 
Detection of ROS.  Cells were harvested, washed twice with PBS, and then incubated with 
DCF-DA at a final concentration of 10µM for 15 minutes at 37°C in the dark.  Cells were 
then washed once with PBS and analyzed immediately by flow cytometry. 
Cell death staining.  Cells were harvested and washed twice with cold PBS.  5x105 cells 
were resuspended in 100 µl Annexin binding buffer (BD Pharmagen, San Diego, CA) and 
stained with Annexin V (BD Pharmagen; 1:20) and 7-Amino-actinomycin D (BD 
Pharmigen; 1:50) or Propidium Iodide (BD Pharmigen; 1:20) at RT in the dark for 15 
minutes.  400µl binding buffer was subsequently added and the cells were analyzed 
immediately by flow cytometry. 
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Antibodies.  Phospho-JNK (T183/Y185), JNK, Phospho-c-jun (S73), c-jun, and cleaved 
caspase 3 (Asp175), caspase 3 and IκBα were obtained from Cell Signaling Technologies 
(Danvers, MA).  β-tubulin was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
β-actin was obtained from Calbiochem. 
Western blotting.  Cells were harvested, washed twice with cold PBS and resuspended in 
lysis buffer (50 mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 
1mM EDTA, 1mM EGTA, 1mM Na3VO4) supplemented with protease and phosphatase 
inhibitors (Roche, Indianapolis, IN).  Cells were incubated on ice for 15 minutes and the 
lysates were clarified by centrifugation.  Equal amounts of lysates (30-50µg) were subjected 
to SDS-PAGE, transferred onto a nitrocellulose membrane, blocked for 1 hour at room 
temperature in tris buffered saline with 0.05% Tween-20 and 5% non-fat milk and incubated 
with the indicated antibodies overnight.  Blots were incubated with the appropriate secondary 
antibody for 45 minutes at room temperature and developed using ECL detection reagent 
(GE, Buckinghamshire, UK). 
Quantitative Real-time PCR.  Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA), digested with DNase I (Promega, Madison, WI), and used for reverse 
transcription (SuperScript II kit, Invitrogen). All Taqman primers were obtained from 
Applied Biosystems (Foster City, CA).  Expression levels of GusB were used to normalize 
the amount of the investigated transcripts. 
Viral Production and Transduction.  Virus was produced by transient transfection of 293T 
cells with pCL-10A1 (Imgenex, San Diego, CA) and a retroviral vector using Fugene at a 1:1 
ratio.  Viral supernatant was collected 24 and 48 hours post-transfection and concentrated 
using centrifugal filter units (Amicon Ultra, Millipore, Billerica, MA).  Target cells were 
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resuspended at 0.5x106 cells/ml in RPMI with viral supernatant in 6-well plates and spun at 
2500 rpm for 1 hour at room temperature.  Cells were incubated with viral supernatant for an 
additional 3 hours at 37°C and then plated in RPMI for an additional 24-48 hours before 
harvest for experiments. 
 
3.4 Results 
Inhibition of IKKβ results in apoptosis of BCR-ABL-expressing cells. 
Recently, we and others have shown that IKKβ activity is required for survival of 
BCR-ABL-expressing myeloid cells, including cells with mutations resistant to the 
commonly used BCR-ABL inhibitors Imatinib and Dasatinib (Duncan et al., 2008, Cilloni et 
al., 2006).  That data showed the importance of IKKβ in BCR-ABL-induced oncogenesis. 
However a mechanism mediating IKK inhibitor-induced cell death and involvement of NF-
κB in cell survival was not shown. As analyzed before, cell viability was measured to 
determine the effect of IKKβ inhibition using Compound A (a well validated IKKβ inhibitor, 
Ziegelbauer et al., 2005) in parental 32D cells and in 32D cells stably expressing BCR-ABL 
p185 (32D/p185). Compound A treatment resulted in decreased cell viability similar to 
treatment with Imatinib, while Compound C, an inactive analog of Compound A, did not 
affect the viability of 32D/p185 cells (Fig. 3.1A and see Duncan et al., 2008). The decrease 
in cell viability with Compound A treatment corresponds with cleavage of caspase 3, a 
marker of apoptosis (Fig. 3.1B).  Similar results were seen in parental BaF3 pro-B cells and 
BaF3 cells expressing BCR-ABL (Fig. S3.1).  Co-incubation with ZVAD-FMK, an inhibitor 
of caspase activation, potently blocks Compound A-induced cell death (Fig. 3.1B and 3.1C; 
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Duncan et al, 2008). These results show that IKKβ activity is required to block apoptosis in 
cells expressing BCR-ABL. 
 
NF-κB activity is required for the survival of BCR-ABL-expressing cells. 
Although IKKβ is known to activate NF-κB through the phosphorylation-mediated 
ubiquitination and degradation of IκBα, it also has other targets (Hu et al., 2004; Lee et al., 
2007).  Therefore, to determine if NF-κB is necessary for the survival of BCR-ABL-
expressing cells downstream of IKKβ, and to rule out off target effects of Compound A, NF-
κB activity was blocked by expressing IκBα super-repressor (IκBα-SR), a form of IκBα 
containing serine to alanine mutations at residues 32 and 36 that prevent its phosphorylation 
and degradation, thereby sequestering NF-κB in the cytoplasm of the cell.  Expression of 
IκBα-SR led to apoptosis in BCR-ABL-expressing 32D cells over time as measured by 
Annexin V/PI staining (Fig. 3.2A) and expression of cleaved caspase 3 (Fig. 3.2B) while the 
viability of cells transduced with empty vector were not affected.  Taken together, these 
results show a requirement for NF-κB activity downstream of IKKβ in hematopoietic cells 
expressing BCR-ABL to prevent apoptosis. 
 
IKKβ inhibition in BCR-ABL-expressing cells results in the accumulation of intracellular 
oxygen species. 
While the inhibition of both IKKβ and NF-κB in BCR-ABL-expressing cells results 
in apoptosis, the mechanism that precedes cell death remains unclear.  Cells that have 
undergone oncogenic transformation, including those overexpressing Ras, c-myc and BCR-
ABL, have increased levels of intracellular ROS (Irani et al., 1997, Vafa et al. 2002, Sattler et 
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al., 2000).  Transformed cells utilize increased ROS as secondary signaling molecules to 
enhance proliferation and tumor development.  However, because transformed cells harbor 
higher levels of ROS, a further increase in free radicals can result in apoptosis or necrosis 
(Pelicano et al, 2004).  As BCR-ABL expression is known to enhance reactive oxygen 
species production in hematopoietic cells (Sattler et al, 2000; Kim et al, 2005; Naughton et 
al, 2009) and NF-κB can regulate antioxidant gene expression (Tang et al, 2002; Pham et al, 
2004; Kamata et al, 2005), we asked if IKKβ inhibition with Compound A results in altered 
ROS levels leading to cell death.  Relative ROS levels were measured in 32D/p185 cells 
treated with Imatinib or Compound A over time.  Treatment with the BCR-ABL inhibitor 
Imatinib decreased intracellular ROS levels (Fig. 3.3A) as previously reported (Sattler et al., 
2000), while IKKβ inhibition using Compound A caused an increase in intracellular ROS as 
measured by DCF-DA staining.  Cells treated for 12 to 16 hours showed an accumulation of 
ROS (Fig. 3.3) while cells treated for 1 hour did not (data not shown), suggesting that an 
indirect mechanism leads to the accumulation of ROS in these cells.  The accumulation of 
ROS upon treatment with Compound A is reversed through the addition of antioxidants n-
acetyl-cysteine (NAC) or butylated hydroxyanisole (BHA) (Fig. 3.3B).  These data indicate 
that IKKβ inhibition leads to significantly enhanced levels of ROS, over those induced by 
BCR-ABL. 
 
NF-κB inhibits the activation of JNK downstream of BCR-ABL to promote cell survival. 
At high levels, ROS have been shown to activate AP-1, resulting in cell death (Shen 
and Liu, 2006).  Interestingly, NF-κB is important for the regulation of JNK, an upstream 
effector of AP-1, to block death under cell stress conditions (Tang et al., 2002; Pham et al, 
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2004; Kamata et al, 2005).  Given the correlation between increased intracellular ROS and 
apoptosis in BCR-ABL-expressing cells after Compound A treatment, we asked if NF-κB 
activation is important for the regulation of intracellular ROS and inhibition of JNK 
downstream of BCR-ABL.  A time course in which 32D/p185 cells were treated with 
Compound A shows that both the phosphorylation of JNK, its downstream target c-jun, and 
caspase-3 cleavage occur 6 hours after treatment (Fig. 3.4A).  32D/p185 cells were 
transduced with empty vector or IκBα-SR to examine the effect of NF-κB inhibition on JNK 
activation and apoptosis downstream of BCR-ABL.  Cells harvested 36 hours post-
transduction showed increased phosphorylation of JNK, c-jun and the cleavage of caspase 3 
(Fig. 3.4B). Parental 32D cells expressing IκBα-SR were not affected to the same extent as 
32D/p185 cells, although some apoptosis is apparent as measured by cleavage of caspase 3 
(Fig. 3.4C).  This low level of cell death can be attributed to moderate activation of NF-κB in 
these cells due to their dependence on IL-3 for survival (Reuther et al., 1998).  While IL-3 is 
also known to activate JNK (Yu et al., 2004), expression of IκBα-SR did affect JNK 
phosphorylation in these cells.  Together, these data show that NF-κB actively regulates the 
level of intracellular ROS and also inhibits the activation of JNK downstream of BCR-ABL 
to inhibit cells from undergoing apoptosis. 
 
IKKβ inhibition leads to downregulation of transcription of antioxidant genes. 
Our results show that NF-κB activity is important for the regulation of intracellular 
ROS and JNK activity downstream of BCR-ABL to prevent cells from undergoing apoptosis.  
NF-κB is known to regulate the expression of genes encoding proteins with antioxidant 
properties (Kamata et al., 2005; Pham et al, 2004).  Due to the increase in intracellular ROS 
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upon inhibition of IKKβ, we asked if NF-κB transcriptionally regulates genes known to clear 
excess ROS from the cell.  BCR-ABL-expressing cells were treated with vehicle or 
Compound A and quantitative real-time PCR was used to screen NF-κB target genes known 
to have antioxidant properties.  32D/p185 cells treated with Compound A for 12 hours 
showed decreased levels of both Sod2 and Fth1 mRNAs (Fig. 3.5A), corresponding with the 
phosphorylation of JNK and apoptosis (Fig. 3.4A).  This result indicates that blocking IKKβ 
activity results in decreased production of two known ROS scavengers, possibly resulting in 
accumulation of intracellular ROS and apoptosis.  To rule out potential off target effects of 
Compound A, IκBα-SR was overexpressed to block NF-κB activity in 32D/p185 cells.  
Similar to the results obtained using Compound A treatment, cells expressing IκBα-SR (Fig. 
3.5C) also showed decreased mRNA levels of Sod2 and Fth1 (Fig. 3.5B), correlating with 
apoptosis as measured by cleavage of caspase 3. Overexpression of Sod2 and Fth1 did not 
rescue the cell death response induced by IKKβ inhibition (data not shown), suggesting that 
multiple mechanisms controlled by IKK and NF-κB contribute to the control of ROS levels 
in oncogenically transformed cells. 
 
JNK inhibition rescues BCR-ABL+ cells from apoptosis after Compound A treatment. 
Our results show that NF-κB activity regulates intracellular ROS levels and JNK 
activation in BCR-ABL-expressing cells.  To determine the importance of JNK activity in the 
death of BCR-ABL-expressing cells after inhibition of NF-κB, we blocked JNK using a 
specific inhibitor, SP600125, and treated 32D/p185 cells with Compound A.  Cells that were 
treated with SP600125 and Compound A showed decreased apoptosis as indicated by 
caspase 3 cleavage (Fig. 3.6A) and FACS analysis (Fig. 3.6B).  However, cells treated with 
 61 
high concentrations of SP600125 (≥25µM) underwent apoptosis without IKKβ inhibition, 
indicating that BCR-ABL-expressing cells also require low levels of JNK activity for 
survival as previously shown (Raitano et al, 1995; Hess et al., 2002).  Similar results were 
obtained from 32D/p185 cells that were treated with SP600125 upon expression of IκBα-SR 
(Fig. 3.6C).  These data show that increased JNK activity is required for cell death in BCR-
ABL-expressing cells when NF-κB is inhibited.  These data further suggest an important role 
for JNK regulation and evasion of apoptosis by NF-κB downstream of BCR-ABL. 
 
Inhibition of ROS prevents death due to IKKβ inhibition in BCR-ABL+ cells. 
The increase in intracellular ROS in transformed cells enhances proliferation and 
tumorigenicity.  However, these cells are also sensitive to further increases in intracellular 
ROS, which may lead to apoptosis (Pelicano et al, 2004).  Our data show that inhibition of 
NF-κB leads to a further increase in intracellular ROS, activation of JNK and apoptosis 
downstream of BCR-ABL.  To better understand the role of NF-κB in the regulation of 
intracellular ROS in cells expressing BCR-ABL, we inhibited ROS and measured cell death 
after Compound A treatment.  Interestingly, 32D/p185 cells incubated with n-acetyl-cysteine 
(NAC) or butylated hydroxyanisole (BHA) in conjunction with Compound A treatment 
showed a pronounced decrease in phosphorylated JNK and were resistant to apoptosis (Fig. 
3.7A and 3.7B).  Similar results were obtained in Ba/F3 cells expressing BCR-ABL (Fig. 
S3.2).  Cells were also co-incubated with bovine catalase and Compound A, resulting in 
decreased JNK phosphorylation and apoptosis (Fig. 3.7C).  Lastly, 32D/p185 cells were 
incubated with NAC upon expression of IκBα-SR as determined by expression of green 
fluorescent protein.  JNK activation and apoptosis induced by the overexpression of IκBα-SR 
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were also inhibited by NAC treatment (Fig. 3.7D).  These results show that NF-κB activity is 
required to regulate increased intracellular ROS following transformation with BCR-ABL.  
Upon inhibition of NF-κB, the accumulation of ROS in the cell leads to the activation of JNK 
and apoptosis (Fig. 3.8). 
 
3.5 Discussion 
Increased ROS has been documented in several cell types after oncogenic 
transformation and in various cancers (Benhar et al., 2002, Pelicano et al., 2004).  It was first 
discovered that human tumor cells produce increased amounts of hydrogen peroxide 
(Szatrowski and Nathan, 1991), leading to the hypothesis that cancer cells are subject to 
persistent oxidative stress, possibly explaining characteristics of cancer including genomic 
instability and increased proliferation (Toyokuni et al., 1995).  Indeed, several reports have 
shown an increase in reactive oxygen species in primary human tumors, including brain (Iida 
et al., 2001), colorectal carcinoma (Toyokuni et al., 1999), and ovarian cancer (Senthil et al., 
2004).  Additionally, reports showed that oncogenic transformation by Ras, c-myc and BCR-
ABL lead to increased ROS which important for increased proliferation and tumorigenic 
potential (Irani et al., 1997; Felsher et al., 1999; Vafa et al., 2002, Sattler et al., 2000; Kim et 
al, 2005; Naughton et al, 2009). 
Relative to oncogenic Ras expression, increased ROS levels were shown to be 
required for cellular transformation (Irani et al., 1997). In this regard, ROS generated from 
the Qo site of mitochondrial complex III is required for anchorage-independent growth of 
Ras-transformed cells (Weinberg et al, 2010).  Overexpression of Nox1, a superoxide 
generator, in NIH3T3 results in elevated production of ROS and a transformed phenotype 
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with increased proliferation (Suh et al., 1999).  Interestingly, Nox1 knockdown blocks Ras-
transformed phenotypes including anchorage independent growth in vitro and in vivo 
(Mitsushita et al., 2004).  Relative to our study, ROS levels are increased downstream of 
BCR-ABL which leads to increased PI3K/Akt-dependent signaling through inhibition of the 
phosphatase PP1a (Naughton et al., 2009). 
Cells transformed with BCR-ABL have increased ROS (Sattler et al, 2000; Kim et al, 
2005; Naughton et al, 2009) (and see Fig. 3.3A ) thus increasing the sensitivity of these cells 
to a further increase in ROS.  Treatment with agents that cause an increase in ROS in BCR-
ABL-expressing cells causes to death (Zhou et al, 2003; Chandra et al., 2006; Trachootham 
et al., 2006; Zhang et al., 2008; Mao et al, 2010).  One such agent, phenethyl isothiocyanate 
(PEITC) results in increased ROS and subsequent apoptosis in cells expressing both wild-
type (Trachootham et al., 2006) and Imatinib- and Dasatinib-resistant (Zhang et al., 2008) 
forms of BCR-ABL.  However, the mechanism by which these compounds cause increased 
ROS and cell death is largely unknown. 
Data described above indicate that the maintenance of moderate levels of ROS are 
necessary for increased proliferative capacity and tumorigenic potential while avoiding death 
in response to excessive accumulation of free radicals (Schimmel and Bauer., 2002; Benhar 
et al., 2002; Pelicano et al., 2004).  Due to excessive strain on ROS clearing mechanisms that 
maintain a moderate balance of ROS, a further increase in ROS in transformed cells may 
result in cancer cell death (Benhar et al., 2002; Pelicano et al. 2004), offering a novel 
approach to target cancer cells. 
Potential therapeutic targets to increase ROS specifically in cancer cells include 
transcription factors that control the expression of both antiapoptotic and antioxidant genes.  
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One such transcription factor, NF-κB, has been shown to regulate the transcription of genes 
with antioxidant properties, such as ferritin heavy chain (Pham et al., 2004) and superoxide 
dismutates (Kamata et al., 2005).  NF-κB also inhibits JNK activation downstream of ROS 
through transcription of genes such as Gadd45 (De Smaele et al., 2001) and XIAP (Tang et 
al., 2001) and through the inhibition of MAPK (Kamata et al., 2005) and tyrosine 
phosphatases (Sattler et al., 2000). 
Our results show an important role for NF-κB activity in the maintenance of 
intracellular ROS and the inhibition of JNK activity downstream of BCR-ABL to prevent 
cell death after oncogenic transformation.  Inhibition of IKKβ using a chemical inhibitor, 
Compound A, results in apoptosis (Fig. 3.1), along with the accumulation of intracellular 
ROS and the activation of JNK in BCR-ABL-expressing cells (Fig. 3.3).  Likewise, 
expression of IκBα-SR, which blocks NF-κB activity, induces JNK phosphorylation and 
apoptosis (Fig. 3.4B).  These data correlate with previous reports in which NF-κB plays an 
important role in JNK inhibition when ROS levels increase (Sakon et al., 2003; Pham et al., 
2004; Kamata et al., 2005). 
Treatment with Compound A or expression of IκBα-SR also results in decreased 
expression of two NF-κB target genes with antioxidant properties, Fth1 and Sod2 (Fig. 3.5).  
These genes have been documented in response to TNFα stimulation in which TNFα-induced 
ROS was scavenged thereby protecting cells from TNFα induced death in the absence of NF-
κB (Pham et al., 2004, Kamata et al., 2005). While inhibition of NF-κB results in decreased 
antioxidant gene expression (Fth1 and Sod2), our preliminary data indicates that 
overexpression of either FTH1 or SOD2 in BCR-ABL-expressing cells is not sufficient to 
inhibit apoptosis in the absence of NF-κB activity.  This is not surprising, as many cellular 
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processes control the levels of ROS, indicating that other NF-κB-dependent genes and 
buffering systems are likely involved in this process.   
Our data also show that JNK activity is involved in the initiation of apoptosis in the 
absence of NF-κB.  Blocking JNK activity with a chemical inhibitor, SP600125, results in a 
decrease in cell death upon Compound A treatment downstream of BCR-ABL (Fig. 3.6).  
However, cells expressing BCR-ABL appear to require JNK activity, as the inhibitor alone 
results in induction of apoptosis in 32D/p185 cells.  Importantly, JNK activation by ROS is 
required for the initiation of apoptosis in the absence of NF-κB activity (Fig. 3.7).  However, 
inhibition of ROS with antioxidants offers more complete protection from Compound A-
induced apoptosis that inhibition of JNK with SP600125.  This could simply be due to the 
efficiency of inhibition by these compounds, or the differences in survival could indicate a 
more involved role for increased ROS in apoptosis after inhibition of NF-κB.  It is probable 
that ROS activate JNK as well as other proteins in the cell to initiate apoptosis in response to 
unfavorable conditions, and that inhibiting JNK only partially blocks the effect of increased 
ROS on cell survival. 
These data show that NF-κB is required to maintain moderate levels of ROS and 
inhibit JNK activation downstream of BCR-ABL-induced ROS to inhibit the induction of 
apoptosis in a model of chronic myeloid leukemia.  As increased ROS is common among 
transformed cells, it is likely that NF-κB plays an essential role in the regulation of ROS to 
prevent death, illustrating the potential use for IKKβ inhibitors as a therapeutic in CML and 
possibly other cancers. 
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Figure 3.1. Inhibition of IKKβ causes apoptosis in BCR-ABL-expressing myeloid cells.  (A) 
32D cells expressing BCR-ABL (32D/p185) were incubated with 1µM Imatinib, IKK inhibitor 
(Compound A) or inactive analog of Compound A (Compound C) for 20 hours.  Cell viability was 
measured by MTS reduction. (B) 32D/p185 cells were coincubated with Z-VAD-FMK (100µM) and 
DMSO (vehicle control) or Compound A for 20 hours.  Cells were stained with propidium iodide 
and annexin V and cell death was measured  by FACS analysis or (C) lysed and analyzed by 
immunoblot. 
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Figure 3.2. NF-κB activity is required for survival of BCR-ABL-expressing cells.  (A) 
32D/p185 cells were transduced with retrovirus expressing vector control or IκBα 
superrepressor (IκBα-SR).  Cells were harvested 36 hours after retroviral transduction and 
stained with propidium iodide and Annexin V.  Cell death was analysed by FACS, or (B) 
analyzed by immunoblot. 
 
 
 
  
 
Figure 3.3. Inhibition of NF-κB causes an increase in intracellular ROS in cells 
expressing BCR-ABL.  (A) 32D/p185 cell were incubated with DMSO (vehicle control) or 
1µM Imatinib or Compound A for 16 hours without or (B) with antioxidants.  Cells were 
then incubated with DCF-DA and fluorescence was measured my FACS analysis. 
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Figure 3.4.  IKKβ inhibition downstream of BCR-ABL induces JNK activation and 
apoptosis.  (A) 32D/p185 cells were treated with DMSO or 1µM Compound A over a time 
course.  Cells were lysed and subjected to immunoblotting. (B) 32D/p185 or (C) parental 
32D cells were transduced with retrovirus expressing vector control or IκBα superrepressor 
(IκBα-SR) and harvested 36 hours after retroviral transduction, lysed and subjected to 
immunoblotting. 
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Figure 3.5.  NF-κB regulates antioxidant gene expression in BCR-ABL-expressing cells. 
(A) 32D/p185 cells were treated for 12 hours with DMSO or 1µM Compound A.  RNA was 
purified using Trizol and then subjected to reverse transcription before analysis using 
quantitative real-time PCR. (B) 32D/p185 cells transduced with retrovirus expressing empty 
vector or IκBα-SR.  Gene expression was analyzed by quantitative real-time PCR as 
described. (C) Expression levels of IκBα of cells used in panel B. 
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Figure 3.6. JNK activation in the absence of NF-κB activity leads to apoptosis in BCR-
ABL-expressing cells. (A) 32D/p185 cells were pretreated with vehicle or indicated 
concentrations of SP600125 for 1 hour.  1µM Compound or DMSO were then added and 
cells were incubated for an additional 24 hours.  Cells were then harvested, lysed and 
subjected to immunoblot. (B) 32D/p185 cells were incubated with vehicle or 25 µM 
SP600125 for 1 hour prior to the addition of DMSO of 1µM Compound A.  Cells were 
stained using Annexin V and propidium iodide.  Cell death was measured by FACS. (C) 
32D/p185 cell were transduced with IκBα-SR.  20 hours post-transduction, cells were treated 
with SP600125 additional 8 hours.  Cells were then lysed and analyzed by immunoblot. 
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Figure 3.7.  Antioxidants rescue BCR-ABL-expressing cells from death when NF-κB is 
inhibited.  32D/p185 cells were pretreated with vehicle, 20mM NAC or 50µM BHA for 1 
hour prior to the addition of DMSO or 1µM Compound A.  Cells were incubated for an 
additional 20 hours and  (A) lysed and subjected to immunoblot, or (B) stained with Annexin 
V and propidium iodide and analyzed using flow cytometry.  (C) 32D/p185 cells were 
pretreated with bovine catalase for 1 hour prior to the addition of DMSO or 1µM Compound 
A.  Cells were incubated for an additional 20 hours and then harvested for immunoblot.  (D) 
32D/p185 cells were transduced with retrovirus expressing empty vector or IκBα-SR.  24 
hours after transduction, cells were replated in media with or without 20µM NAC for an 
additional 12 hours.  Cells were harvested, lysed and used for immunoblotting. 
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Figure 3.8. NF-κB activity is required for the survival of BCR-ABL-expressing cells 
through the regulation of ROS and JNK.   
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Supplemental figure 3.1. IKKβ inhibition induces JNK activation and apoptosis in Ba/F3 cells 
expressing p210 BCR-ABL.  BaF3/p210 cells were treated with DMSO or 1µM Compound A over 
a time course.  Cells were harvested, lysed and analyzed by immunoblot. 
 
clvd. casp. 3 
Actin 
D
M
S
O
 
C
pA
 
D
M
S
O
 
C
pA
 
D
M
S
O
 
C
pA
 
p-c-jun (S73) 
p-JNK (T183/Y185) 
JNK 
c-jun 
6 hr 12 hr 18 hr 
Supplemental figure 1.  BaF3/p210 cells were treated with DMSO or 1µM 
Compound A over a time course.  Cells were harvested, lysed and analyzed by 
immunoblot. 
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Supplemental figure 3.2.  Antioxidant treatment rescues Ba/F3 cells expressing p210 BCR-
ABL from compound A-induced apoptosis.  BaF3/p210 cells were pretreated with antioxidants 
NAC (20mM) or BHA (50µM) for 1 hour.  Cells were subsequently treated with DMSO or 1µM 
Compound A for 16 hours.  Cells were harvested, lysed and analyzed by immunoblot. 
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Supplemental figure 2.  BaF3/p210 cells were pretreated with antioxidants NAC 
(20mM) or BHA (50µM) for 1 hour.  Cells were subsequently treated with DMSO or 
1µM Compound A for 16 hours.  Cells were harvested, lysed and analyzed by 
immunoblot. 
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CHAPTER IV 
 
INVESTIGATION OF NF-κB AS A THERAPEUTIC TARGET IN CHRONIC MYELOID 
LEUKEMIA 
 
Abstract 
Treatment of chronic myeloid leukemic (CML) with current therapeutics allows 
patients to successfully manage disease burden, but rarely eliminates the disease.  Leukemia 
stem cells, hematopoietic stem cells that express the oncoprotein BCR-ABL, are thought to 
drive the development and maintenance of CML.  Current BCR-ABL inhibitors, including 
imatinib, are unable to target leukemia stem cells.  Therefore, novel therapeutics are needed 
to target leukemia stem cells, potentially eradicating disease.  Here, we investigate the role of 
the NF-κB subunit p65 in BCR-ABL-driven transformation of hematopoietic stem and 
progenitor cells (HSPCs), as well as the effect of IKKβ inhibition on colony formation in 
vitro.  Results show that p65 is important for BCR-ABL-mediated transformation and 
development of disease in vivo.  Colony formation by BCR-ABL-expressing HSPCs is 
attenuated with IKKβ inhibition.  Ongoing experiments aim to determine the importance of 
p65 in the maintenance of CML, as well as the ability of IKKβ to target the leukemia stem 
cell population.  In summary, NF-κB is important for development and maintenance of CML 
and is a promising therapeutic target for the treatment of chronic-phase and blast-crisis CML. 
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Introduction 
Chronic myeloid leukemia is a malignant clonal disorder of hematopoietic stem cells 
that results in increased and deregulated growth of myeloid cells.  About 95% of CML cases 
arise from the formation of the Philadelphia (Ph) chromosome, the product of a chromosomal 
translocation that results in the expression of the BCR-ABL fusion protein, which is a 
constitutively active tyrosine kinase (Sawyers, 1999).  As a consequence of increased 
tyrosine kinase activity, BCR-ABL can phosphorylate a variety of substrates and activate 
multiple signaling cascades, affecting the growth and differentiation of cells. 
CML is characterized by distinct clinical phases.  During the chronic phase, mature 
granulocytes are produced, but patients have an increased number of myeloid progenitor cells 
in the peripheral blood.  As the disease progresses, patients enter accelerated phase followed 
by blast crisis, where hematopoietic differentiation is inhibited and immature blasts 
accumulate in the bone marrow, spilling into the circulation (Melo and Barnes, 2007).  
Current treatment options for CML include the BCR-ABL tyrosine kinase inhibitor, Imatinib, 
as well as second-generation inhibitors such as Dasatinib, which block the binding of ATP to 
the BCR-ABL tyrosine kinase, inhibiting its ability to phosphorylate downstream protein 
targets.  Patients must continue Imatinib treatment indefinitely to keep the disease in 
remission.  However, the effectiveness of Imatinib decreases greatly in patients in the 
accelerated or blast-crisis phases of the disease (Druker et al., 2006). 
Hematopoiesis in CML is organized into a hierarchy that resembles that of normal 
hematopoiesis.  The production of leukemic progeny is fueled by the presence of leukemic 
cells with self-renewing properties, known as leukemia stem cells (Ren, 2005).  CML stem 
cells initiate disease as a result of increased BCR-ABL kinase activity, even in the presence 
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of imatinib.  Human CML stem cells, defined as CD34+ CD38-, are resistant to tyrosine 
kinase inhibitors regardless of their mutation status (Copland et al., 2006).  Patients 
successfully treated with Imatinib have residual BCR-ABL-expressing CD34+CD38- cells 
(Graham et al., 2002), and the elimination of CML stem cells in chronic phase by other 
available agents is also unsuccessful (reviewed by Jamieson, 2008).  These data highlight the 
need for therapeutics that effectively target leukemia stem cells. 
Mouse models of CML have been developed to study disease characteristics and to 
uncover novel therapeutic targets.  One model is induced through the transplantation of 
hematopoietic stem and progenitor cells (HSPCs), transduced with a BCR-ABL retrovirus, 
into lethally irradiated recipients (Daley et al., 1990), giving rise to a CML-like disease.  In 
this model, fluorescent proteins can be used to track BCR-ABL-expressing cells in vivo.  
However, due to the nature of viral infection, quiescent stem cells cannot be used to give rise 
to CML in this model, bringing into question its validity when studying CML stem cells.  A 
second model utilizes the inducible expression of BCR-ABL in transgenic mice.  In these 
animals, transgene expression, under the control of the Scl promoter, is directed by a 
tetracycline-responsive element.  Scl is expressed in hematopoietic stem and progenitor cells, 
and this system also allows for the development of a CML-like disease in vivo (Huettner et 
al., 2000).  Using this model, recent evidence has shown that leukemia stem cells reside in 
the long-term hematopoietic stem cell compartment, as defined by the markers lineage 
negative, Sca-1 positive, c-kit positive and Flk2 (Flt3) negative, CD150 positive (Reynaud et 
al., 2011), and has shown that this model is useful for the study of CML stem cells. 
Here, we analyze the efficacy of NF-κB inhibition as a therapeutic target in CML.  
Previous work has shown that BCR-ABL requires NF-κB to efficiently transform 
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hematopoietic cells (Reuther et al., 1998), and that NF-κB is required for the survival of 
BCR-ABL-expressing cell lines (Duncan et al., 2008) through the regulation of antioxidant 
genes and inhibition of JNK-induced apoptosis (Stein and Baldwin, 2011).  While effective 
at inducing apoptosis using in vitro systems, the efficacy of NF-κB inhibition in an in vivo 
model of CML has not been determined.  Our data show that NF-κB, specifically the p65 
subunit, is required for efficient transformation of HSPCs by BCR-ABL, and to induce 
disease in vivo.  Treatment of BCR-ABL-expressing HSPCs in vitro with an IKKβ inhibitor, 
compound A, reduces colony formation, indicating that inhibition of NF-κB through IKKβ is 
a potential therapeutic for CML.  Further investigation of NF-κB inhibition through the 
deletion of p65, or through the inhibition of IKKβ in mice that have developed CML is 
ongoing. 
 
Materials and Methods 
Animal husbandry. Vav-Cre (B6.Cg-Tg(Vav1-cre)A2Kio/J; stock #008610) and Mx-Cre 
(B6.Cg-Tg(Mx1-cre)1Cgn/J; stock #003556), and Pep Boy (B6.SJL-Ptprca Pepcb/BoyJ; stock 
#002014) mice were obtained from Jackson labs.  p65 conditional mice have been described 
previously (Steinbrecher et al., 2008).  All animals were housed in accordance with protocols 
approved by the University of North Carolina Institutional Animal Care and Use Committee. 
Plasmids and Viral Production.  MSCV-BCR-ABL-IRES-GFP (pMIG-BCR-ABL) was 
kindly provided by Dr. Craig Jordan.  pMIG-BCR-ABL was transfected along with pCL-Eco 
(Addgene #12371) in Phoenix-ECO packaging cells (ATCC).  Virus was collected 48- and 
72- hours post-transfection and stored at -80. 
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Isolation and Transduction of HSPCs.  Bone marrow was extracted from the femurs and 
tibias of mice, RBC lysed, and then Sca-1-expressing cells were isolated with a StemCell 
Technologies EasySep Sca-1 Biotin kit following the manufacturer’s instructions.  Cells were 
then incubated overnight in cytokine stimulation media (Iscove's Modified Dulbecco's 
Medium supplemented with 10% heat-inactivated fetal bovine serum, stem cell factor 
(100ng/ml), Flt3 (100ng/ml), IL-3 (20ng/ml), IL-6 (20ng/ml) and penicillin/streptomycin; all 
cytokines from Peptrotech).  The following day, cells were resuspended in viral infection 
media and transferred to a dish coated with retronectin (Takara).  Virus was added and cells 
were spun at 1200 x g for 60 minutes, and then returned to the incubator.  6 hours later, half 
of the supernatant was replaced with fresh virus and cells were incubated overnight.  Cells 
were spun with virus following the same steps the next day.  On day 4, cells were again spun 
with virus, and then, 6-hours later, viral infection efficiency was determined by GFP 
expression using flow cytometry.  Cells were then used for experiments. 
Generation of the in vivo CML Model.  Equal numbers of viral transduced cells were 
injected into the lateral tail vein of lethally irradiated Pep Boy/J (CD45.1) recipients.  
Animals were monitored daily for signs of disease. 
Quantitative Real-time PCR.  Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA), digested with DNase I (Promega, Madison, WI), and used for reverse 
transcription (SuperScript II kit, Invitrogen). All Taqman primers were obtained from 
Applied Biosystems (Foster City, CA).  Expression levels of GusB were used to normalize 
the amount of the investigated transcripts. 
Flow cytometry.  Bone marrow was Fc blocked and then stained with fluorochrome-
conjugated antibodies to CD45.2 (Biolegend clone 104), Gr-1 (eBiosciences clone RB6-8C5) 
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and CD11b (eBiosciences clone M1/70). For cell death assays, cells were stained with 
Annexin V following the manufacturer’s instructions.  Samples were analyzed on a 
Beckman-Coulter CyAn ADP.  All flow cytometry data was analyzed using TreeStar FlowJo 
Colony-formation in vitro.  1000 GFP+ virally-transduced Sca-1+ cells were plated in 1 ml 
methylcellulose media without cytokines (StemCell Technologies) in 24-well plates.  Cells 
were incubated for 10 days and colonies were counted. 
 
Results 
Generation of p65-/- hematopoietic mice. 
 To assess the involvement of the NF-κB subunit p65 in transformation of HSPCs, we 
utilized p65 hematopoietic null (p65hem-/-) mice.  These mice were created by crossing 
conditional p65 mice (p65-loxP) to mice expressing Cre under the control of the Vav 
promoter.  Vav is expressed predominately in the hematopoietic system, including in the 
HSC fraction (de Boer et al., 2003).  The resulting progeny do not express p65 in total bone 
marrow or in the Sca-1-positive fraction, which is enriched for HSPCs (Bryder et al., 2006) 
and used in these studies to isolate HSPCs from whole bone marrow (Figure 4.2A and 4.2B).  
These data indicate that this system is valid for the study of BCR-ABL-mediated 
transformation of hematopoietic cells. 
 
The expression of p65 is important for the development of CML in vivo. 
 NF-κB activity is required for the survival of BCR-ABL-expressing cells through the 
inhibition of JNK-mediated apoptosis (Stein and Baldwin, 2011).  Given that BCR-ABL 
expession renders cells NF-κB dependent, we asked if BCR-ABL-expressing HSPCs could 
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give rise to CML in mice in the absence of p65.  Data show that animals engrafted with wild-
type cells expressing BCR-ABL developed disease and became moribund in about 25 days 
(data not shown).  Mice receiving wild-type cells displayed the accumulation of GFP-
positive cells, indicating the expression of BCR-ABL, in their bone marrow; the majority of 
these cells are myeloid leukemic blasts.  Conversely, mice receiving p65-/- cells showed 
almost no GFP-expressing cells in their bone marrow (Figure 4.2A and 4.2B).  Recipients of 
wild-type cells also developed severe splenomegaly, a symptom common in CML, while p65 
null cells did not give rise to splenomegaly or any other leukemic side effects in recipient 
animals (Figure 4.2C). 
 
Loss of p65 expression impairs oncogenic transformation by BCR-ABL. 
 Previous studies show that NF-κB is important for oncogenic transformation by both 
BCR-ABL (Reuther et al., 1998) and Ras (Finco et al., 1997) through the inhibition of 
apoptosis induced by cell stress (Mayo et al., 1997).  The requirement for p65 was analyzed 
during transformation of HSPCs by BCR-ABL.  Equal numbers of transduced HSPCs were 
plated in methylcellulose media lacking cytokines in order support only growth-factor 
independent cells, which is a hallmark of oncogenic transformation (Hanahan and Weinberg, 
2011).  Importantly, far fewer colonies were formed by BCR-ABL-expressing HSPCs 
lacking p65 (Figure 4.3A).  p65 expression was absent in the colonies that did form (Figure 
4.3B), indicating that p65 is important, but not required, for transformation by BCR-ABL.  
As an important role for NF-κB in oncogenic transformation is through the inhibition of 
apoptosis, flow cytometry was used to analyze apoptosis of BCR-ABL-expressing HSPCs 
after viral infection by Annexin V staining.  The data show no changes in the number of 
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Annexin V/GFP positive or Annexin V positive/GFP negative cells (Figure 4.3C), indicating 
that, at least during the early stages, p65 is not required to inhibit apoptosis in cells 
undergoing oncogenic transformation by BCR-ABL. 
 
IKKβ inhibition decreases colony formation by BCR-ABL-expressing HSPCs in vitro. 
 A main goal of testing novel targets in CML is to uncover a therapeutic that is 
capable of eradicating leukemia stem cells.  CML stem cells are known to be impervious to 
BCR-ABL inhibition by imatinib treatment (Copland et al., 2006), and other BCR-ABL 
inhibitors (Jamieson, 2008).  To analyze the effect of IKKβ inhibition on colony formation in 
vitro, equal numbers of BCR-ABL-expressing HSPCs were plated in methylcellulose media 
without cytokines along with the inhibitors imatinib or compound A.  Cells plated with 
imatinib formed fewer colonies as expected, as did those treated with two different 
concentrations of compound A.  However, the greatest effect occurred in cells treated 
simultaneously with imatinib and compound A (Figure 4.4).  These results indicate that 
compound A is a potential therapeutic in CML, and that a combined treatment strategy may 
effectively target the leukemia stem cell. 
 
Discussion and Future Directions 
 Here, we show that the NF-κB subunit p65 is important for BCR-ABL-driven 
oncogenic transformation of HSPCs (Figure 4.3A).  Cells lacking p65 expression cannot 
undergo oncogenic transformation by BCR-ABL in a manner sufficient to induce CML in 
vivo (Figure 4.2A and 4.2B).  Interestingly and unexpectedly, p65 does not appear to be 
required for the inhibition of apoptosis, at least early on, after BCR-ABL expression in 
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HSPCs (Figure 4.3C).  Lastly, IKKβ inhibition is sufficient to reduce colony formation in 
BCR-ABL transformed HSPCs, while a combination approach with both imatinib and 
compound A almost complete abolished colony formation in vitro (Figure 4.4). 
 While NF-κB appears to be a promising therapeutic target based on these finding and 
others, which show that NF-κB is required for the survival of BCR-ABL-expressing cells 
(Cilloni et al., 2006; Duncan et al., 2008; Lounnas et al., 2009), the effectiveness of IKKβ in 
an in vivo model of CML remains to be determined.  The end goal of uncovering novel 
therapeutics in CML is to target the leukemia stem cell and effectively eradicate the disease 
from patients. Imatinib treatment results in complete molecular remission of only 4% of 
patients (Hughes et al., 2003).  Patients must continue imatinib treatment indefinitely to keep 
CML in remission, and the effectiveness of imatinib decreases greatly in patients in the 
accelerated or blast-crisis phases of the disease (Druker et al., 2006).  As CML stem cells are 
known to be resistant to imatinib treatment (Copland et al., 2006), as well as other agents 
(Jamieson, 2008), characterizing agents capable of targeting the leukemia stem cell is 
necessary. 
 Ongoing studies in our lab aim to uncover the efficacy of NF-κB inhibition in an in 
vivo model of CML.  One study aims to uncover the role of p65 in survival of leukemic 
blasts in mice that have developed CML through the transplantation of BCR-ABL-expressing 
HSPCs that also express an inducible form of Cre.  Once the animals have developed disease, 
p65 will be excised through the induction of Cre expression.  We will also test the impact of 
p65 loss in cells expressing the drug-resistant T315I BCR-ABL mutant (Shah et al., 2004).  
Using the same model, we will also test the ability of IKKβ inhibition to induce apoptosis in 
leukemic blasts expressing both wild-type and mutant BCR-ABL.  The design of this 
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experiment is shown in Figure 4.5.  The goal of this study is to determine if loss of p65 
results in apoptosis of leukemic blasts.  Data collected will be useful in determining how 
important NF-κB is for the survival of BCR-ABL-expressing cells in vivo, as current studies 
in vitro have not taken into account supportive signals from the microenvironment.  Genetic 
deletion results will also act as a comparison for results obtained after IKKβ inhibition with 
compound A to monitor for unexpected off target effects of the inhibitor. 
 The second ongoing study strives to determine if IKKβ inhibition with compound A 
can effectively target CML stem cells in an in vivo.  The design for this study is shown in 
Figure 4.6, and utilizes the inducible model of CML as described.  In this experiment, CML 
will be induced in animals through tetracycline withdrawal, followed by treatment with 
imatinib, compound A, or a combination of the two inhibitors.  Animals will be split into two 
groups and 1) monitored daily for survival analysis, or 2) used for transplantation into 
secondary recipients.  Transplantation into secondary recipients will highlight the self-
renewal capabilities of the leukemia stem cells (Bryder et al., 2006), as they are defined as 
long-term hematopoietic stem cells expressing BCR-ABL (Reynaud et al., 2011).  Limiting 
dilution assays will be used to calculate the frequency of the leukemic stem cell in each 
treatment type.  If treatment is successful, secondary recipients will not develop CML. Use of 
this assay has been used with success to uncover other novel therapeutics that are capable of 
targeting leukemic stem cells in a moue model of CML (Zhang et al., 2010; 2012). 
 These studies, along with current data, will outline the potential of IKKβ inhibitors in 
the clinic for the treatment of CML.  Importantly, compound A can effectively induce 
apoptosis in cell expressing drug resistant mutants of BCR-ABL, such as the T315I mutation, 
and show promise as a therapeutic in both chronic and drug-resistant blast-crisis CML.  
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However, side effects such as toxicity to normal hematopoietic cells, are a concern when 
development novel treatment strategies for leukemias.  These concerns are investigated and 
discussed in Chapters 5 and 6. 
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Figure 4.1. The leukemia stem cell (LSC) hypothesis. 
 
Figure 4.2. Characterization of p65 expression in p65hem-/- mice.  Whole bone marrow 
was extracted from the femurs and tibias of p65hem-/- or littermate controls, and.  A. p65 
expression was analyzed by quantitative real-time PCR, or B. enriched for Sca-1+ HSPCs 
prior to expression analysis for p65 by qRT-PCR. 
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Figure 4.3. p65 expression is require for BCR-ABL-expressing HSPCs to give rise to 
disease in vivo.  Equal numbers of HSPCs expressing BCR-ABL were injected into the 
lateral tail vein of lethally irradiated recipients.  Bone marrow and spleens were harvested 25 
days post-transplant.  A. GFP and myeloid marker (CD11b and Gr-1 expression was 
analyzed in the bone marrow of transplant recipients.  B. The average percentage of 
CD45.2+GFP+ cells in the bone marrow of recipients is displayed.  C. Spleens were weighed 
upon dissection of transplant recipients.  
bone marrow.jo Layout
9/5/12 10:47 AM Page 1 of 1 (FlowJo v9.4.11)
100 101 102 103 104
<FL 1 Log>: GFP
0
20K
40K
60K
S
S
 L
in
: S
S
86
100 101 102 10 3 104
<FL 5 Log>: Gr-1 PE-Cy7
100
101
102
103
104
<F
L 
8 
Lo
g>
: C
D
11
b 
AP
C
87.7
100 101 102 103 104
<FL 1 Log>: GFP
0
20K
40K
60K
S
S
 L
in
: S
S
2.17
100 101 102 10 3 104
<FL 5 Log>: Gr-1 PE-Cy7
100
101
102
103
104
<F
L 
8 
Lo
g>
: C
D
11
b 
AP
C
27
Sp
le
en
 W
ei
gh
t (
g)
WT KO
0.0
0.2
0.4
0.6
0.8
Gr-1+CD11b+ GFP+ 
Gated on CD45.2 
WT 
KO 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
WT KO 
%
C
D
45
.2
+G
FP
+ 
B
on
e 
M
ar
ro
w
 C
el
ls
 
A B 
C 
 
 
92 
 
Figure 4.4.  p65 expression is required for efficient BCR-ABL-driven transformation of 
HSPCs.  HSPCs from p65hem-/- or littermate controls were infected with BCR-ABL retrovirus, 
and A. equal numbers of GFP+ cells were plated in methylcellulose media and then 
incubated for 10 days, at which point colonies were counted.  B. p65 expression in pooled 
colonies was analyzed at day 10 by qRT-PCR.  C. After infection, HSPCs expressing BCR-
ABL were stained with Annexin V and analyzed by flow cytometry to measure apoptosis. 
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Figure 4.5.  IKKβ inhibition effectively impedes colony formation by BCR-ABL-
expressing HSPCs in vitro.  HSPCs from healthy wild-type mice were infected with BCR-
ABL retrovirus, and equal numbers of GFP+ cells were plated in methylcellulose media in 
the presence of the indicated inhibitors.  Cells were then incubated for 10 days, at which 
point colonies were counted.  
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Figure 4.6. Experiment design for the genetic deletion of p65 in animals with CML. 
 
 
 
 
Figure 4.7. Experiment design to determine the efficacy of compound A treatment of 
CML stem cells in vivo. 
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CHAPTER V 
A REQUIREMENT FOR THE NF-κB SUBUNIT p65 IN HEMATOPOIESIS 
 
5.1 Abstract 
Hematopoiesis is a tightly regulated process that results in the production of blood 
cells.  Self-renewal and differentiation of hematopoietic stem cells in a key step in 
hematopoietic development.  Disruption of these steps can lead to altered cell distribution 
and disease.  To determine if the NF-κB subunit RelA/p65 is an important regulator of 
hematopoiesis in vivo, we generated mice lacking RelA/p65 in the hematopoietic 
compartment.  Using this model system, we show that mice lacking RelA/p65 display 
accumulation of hematopoietic stem cells in the bone marrow and spleen, neutrophilia, 
extramedullary hematopoiesis, and decreased hematopoietic stem cell repopulation 
efficiency.  We hypothesize that these phenotypes are due to changes in gene expression that 
lead to decreased self-renewal or differentiation efficiency of hematopoietic stem cell.  Loss 
of RelA/p65 in the hematopoietic stem cell compartment leads to the down regulation of 
genes encoding key factors such as Mpl and Hlf, which promote hematopoietic stem cell 
homeostasis and function, and the upregulation of genes associated with myeloid cell 
differentiation.  These studies demonstrate that p65 is an important regulator of HSC 
maintenance and fate through the regulation of genes required for HSC homeostasis. 
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5.2 Introduction 
Hematopoiesis is the process by which all cellular components of the blood develop.  
The process begins at the hematopoietic stem cell (HSC), a rare cell type that can give rise to 
all lineages of the blood.  HSCs have been characterized extensively and purified (Weissman 
and Shizuru, 2008) from the bone marrow.  A key component to HSC biology is their ability 
to self-renewal as well as to differentiate into other lineages (Weissman, 2000).  These 
properties are essential for HSCs to maintain themselves and to support hematopoiesis over 
an lifetime of the organism.   The balance between self-renewal and differentiation is tightly 
regulated, and is dependent on a variety of signaling pathways (Bryder et al., 2006).  
Normally, HSCs remain relatively quiescent (Passegué et al., 2005) in the endosteal niche, 
where a multitude of factors support either maintenance or differentiation of HSCs (Bryder et 
al., 2006).  One such factor is Mpl, also known as thrombopoietin receptor, which is crucial 
for the maintenance of HSC dormancy (Yoshihara et al., 2007).  Surprisingly, HSCs also 
express a number of transcripts originally thought to be restricted to lineage-restricted cell 
types, suggesting that the transcription of lineage associated genes is necessary to prime cells 
for downstream fates (Miyamoto et al., 2002; Bryder et al., 2006).  HSCs give rise to 
multipotent progenitors, cells that have lost the ability to self-renew, but retained the ability 
to differentiate into all hematopoietic lineages and proliferate much more frequently.  These 
cells then give rise to restricted progenitors, thereby repopulating hematopoietic cells as 
required (Bryder et al., 2006).  Defining pathways involved in the maintenance of self-
renewal and differentiation of HSCs is an important issue in stem biology. 
The NF-κB family of transcription factors is comprised of five family members, p65 
(RelA), RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2).  These proteins share a 
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conserved Rel homology domain, which controls DNA binding, dimerization and interaction 
with inhibitory IκB proteins.  In the classical NF-κB signaling pathway, the subunits p50 and 
p65 are held in an inactive state by IκBα.  Upon stimulation, the activation of the IκB kinase 
(IKK) complex occurs, causing IKKβ to phosphorylate IκBα, resulting in its ubiquitination 
and subsequent degradation.  In the alternative pathway, IKKα homodimers are activated and 
subsequently phosphorylate p100.  This results in the proteolytic processing of p100 to p52 
and allows p52/RelB to translocate to the nucleus.  Once free of its inhibitor, NF-κB is able 
to regulate the expression of a variety of genes, including those encoding cytokines and 
cytokine receptors, and inflammatory and antiapoptotic proteins (Hayden and Ghosh, 2004; 
Bassères and Baldwin, 2006). 
Little evidence describing a requirement for NF-κB in early hematopoiesis exists.  
Mice engrafted with fetal liver cells from rela-/- animals develope all lineages of 
hematopoietic cells and appear to be relatively normal (Alcamo et al., 2002; Igarashi et al., 
2006).  However, animals engrafted with c-rel-/- rela-/- fetal liver cells display decreased 
engraftment efficiency.  Defects in short-term reconstitution have also been suggested, 
although death of recipients is more likely induced by severe anemia and granulocytosis than 
engraftment failure (Grossmann et al., 1999).  More recently, results have shown that 
systemic deletion of both p52 and RelB simultaneously dramatically decreases HSC function 
due to intrinsic and extrinsic factors (Zhao et al., 2012).  Further studies on self-renewal of 
hematopoietic stem cells and differentiation of multipotent progenitors are lacking.  NF-κB is 
known to be an important regulator of both fate and function of lineage-committed cells, 
however.  Genetic deletion models of IKKβ (Greten et al., 2007; Mankan et al., 2011), IκBα 
(Beg et al., 1995) and RelB (Weih et al., 1995) exhibit severe phenotypes including 
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granulocytosis, splenomegaly, and impaired immune response.   Loss of c-rel (Grumont et al., 
1998), NFκB1 (Sha et al., 1995), NFκB2 (Caamaño et al., 1998; Franzoso et al., 1998), and 
animals engrafted with rela-/- fetal liver cells (Horwitz et al., 1997) all display defects in B 
and T cell function. 
Here, we show that the NF-κB subunit p65 is an important regulator of early 
hematopoiesis.  Using a conditional deletion mutant of p65 in the hematopoietic 
compartment, we find that loss of p65 results in accumulation of HSCs, extramedullary 
hematopoiesis, and impaired repopulation ability in transplant recipients.  Gene expression 
studies indicate a key role for NF-κB in the maintenance of HSC homeostasis through the 
control of quiescence and differentiation potential.  Taken together, these data show that p65 
is required for normal hematopoiesis. 
 
5.3 Materials and Methods 
Animal husbandry and drug treatment.  Vav-Cre (B6.Cg-Tg(Vav1-cre)A2Kio/J; stock 
#008610) and Mx-Cre (B6.Cg-Tg(Mx1-cre)1Cgn/J; stock #003556), Pep Boy (B6.SJL-Ptprca 
Pepcb/BoyJ; stock #002014) and B6 (C57BL/6J; stock #000664) mice were obtained from 
Jackson labs.  p65 conditional mice have been described previously (Steinbrecher et al., 
2008).  B6 mice received daily intraperitoneal injections of the IKKβ inhibitor compound A 
(10mg/kg) or vehicle control for 2 weeks.  All animals were housed in accordance with 
protocols approved by the University of North Carolina Institutional Animal Care and Use 
Committee.  Control animals included p65fl/fl littermates (herein: littermates), or Vav-Cre+ 
p65WT/WT mice (herein: wild-type counterparts), as indicated. 
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Tissue processing.  Bone marrow was flushed from the femurs and tibias, subject to RBC 
lysis on ice for 5 minutes and passed through a 70µm filter.  Spleens were gently disrupted 
with frosted glasses slides, subjected to RBC lysis and passed through a 70µm filter.  Blood 
was collected from the submandibular vein or tail vein.  RBCs were lysed and blood was 
stained for flow cytometry. 
Flow cytometry.  After processing, bone marrow and splenocytes were Fc blocked where 
appropriate and then stained with fluorochrome- or biotin-conjugated antibodies.  In some 
instances, streptavidin-conjugated secondary antibodies were used.  A list of antibodies used 
is included as supplementary information.  For cell death assays, cell were stained with 
surface markers and then stained with Annexin V following the manufacturer’s instructions.  
Samples were analyzed on a Beckman-Coulter CyAn ADP.  All flow cytometry data was 
analyzed using TreeStar FlowJo.  Graphs that show “average percent total population” 
indicate the average percentage of the population after doublet exclusion. 
Histopathologic analysis.  Femurs were fixed in 10% saline-buffered formalin, decalcified, 
paraffin embedded, and then sectioned.  Spleens were fixed in 10% saline-buffer formalin, 
paraffin embedded and sectioned.  Sections were then stained with hematoxylin and eosin. 
Complete blood cell counts.  Blood was collected via cardiac puncture into EDTA-coated 
blood tubes.  Samples were analyzed immediately on a Heska’s Animal Blood Counter. 
Immunoblotting.  Processed splenocytes were resuspended in lysis buffer (20 mM Tris-HCl, 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton-X, 2.5 mM sodium 
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, protease cocktail (Sigma), 
phosphatase inhibitor cocktail (Sigma) and incubated on ice for 15 minutes.  Equal amounts 
of clarified lysates were subjected to SDS-PAGE, transferred onto a nitrocellulose 
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membrane, blocked for 1 hour at room temperature in tris buffered saline with 0.05% Tween-
20 and 5% non-fat milk, and incubated with the indicated antibodies overnight.  Blots were 
incubated with the appropriate secondary antibody for 1 hour at room temperature and 
developed using ECL detection reagent (GE, Buckinghamshire, UK).  Primary antibodies 
used for blotting were p65 and b-actin, both from Cell Signaling Technologies.  
Quantitative Real-time PCR.  Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA), digested with DNase I (Promega, Madison, WI), and used for reverse 
transcription (SuperScript II kit, Invitrogen). All Taqman primers were obtained from 
Applied Biosystems (Foster City, CA).  Expression levels of GusB were used to normalize 
the amount of the investigated transcripts. 
Competitive repopulation assays.  Bone marrow was harvested from “test” animals 
(CD45.2) and mixed, as indicated, with healthy “competitor” bone marrow (CD45.1) and 
injected into the lateral tail vein of lethally irradiated Pep Boy recipients.  Recipients were 
irradiated 6-20 hours prior to injections using a Cs-137 source.  Animals were allowed to 
engraft for 20 weeks, at which time peripheral blood was collected, processed as described, 
and analyzed by flow cytometry.  Percentage of CD45.2 versus CD45.1 positive cells in the 
peripheral blood was graphed using Graph Pad Prism. 
Colony-formation in vitro.  100 lineage-Flk2-Sca-1+c-kit+ cells were sorted directly into 1 
ml methylcellulose media with cytokines (Stem Cell Factor, IL-3, IL-6 and Erythropoietin; 
StemCell Technologies M3434) in 24-well plates.  Cells were incubated for 10 days and 
colonies were counted. 
Cell proliferation.  The proliferative index of hematopoietic stem and progenitor cells was 
assessed using a Click-iT EdU Flow Cytometry Assay kit (Invitrogen).  Animals were 
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administered 10µg EdU per gram of body weight via intraperitoneal injection 18 hours prior 
to harvest.  Bone marrow was harvested and stained as described using a modified antibody 
panel (PE and PE-tandem dyes are not compatible with this kit; all clones remained the 
same), and EdU was then detected following the manufacturer’s protocol.  Processed cells 
were analyzed as described. 
Hematopoietic cell homing.  Whole bone marrow was isolated from p65 hematopoietic null 
and wild-type counterparts as described.  2x107 processed whole bone marrow cells were 
injected into the lateral tail vein of lethally irradiated Pep Boy (CD45.1) recipients.  
Recipients were irradiated 24 hours prior to injection using a Cs-137 source.  48-hours post-
injection, recipient femurs and tibias were harvested and bone marrow was processed as 
described for flow cytometry. 
Gene expression analysis of HSCs.  Lineage-Flk2-Sca-1+c-kit+ cells were sorted directly 
into buffer RLT (Qiagen) supplemented with 1% β-Mercaptoethanol.  RNA was extracted 
with a RNEasy Mini Kit (Qiagen) following the manufacturer’s instructions.  RNA was 
amplified and labeled using the Nugen Ovation Pico WTA System V2 and hybridize to 
Affymetrix Mouse Gene Chip 1.0 ST arrays.  Data was normalized using RMA in Partek 
Genomics Suite.  A heat map of genes with a fold-change of ≥2 and a p value of ≤ 0.01 was 
generated using hierarchical clustering. 
 
Results 
Generation of hematopoietic p65 null mice. 
Conventional p65-/- animals die at embryonic day 15 due to liver apoptosis (Beg and 
Baltimore, 1996).  To examine the role of p65 activity in hematopoiesis, conditional 
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knockouts (loxP-p65 mice) were crossed with mice expressing Cre under the control of the 
vav1 promoter.  Vav is an adaptor protein expressed mainly in the hematopoietic system, 
including the stem cell fraction (Almarza et al., 2004; de Boer et al., 2003).  The resulting 
progeny (p65hem-/- mice) are hematopoietic null for p65 (Figure 5.1A).  To ensure complete 
deletion of p65, we examine expression by quantitative real-time PCR analysis.  p65 mRNA 
was not detected in whole bone marrow (Figure 5.1B) or in KLSF cells, a population highly 
enriched for HSCs (Figure 5.1C).  Finally, p65 protein was ablated in splenocytes of p65hem-/- 
mice (Figure 5.1D).  These data show that p65 is efficiently deleted from the hematopoietic 
compartment in this model. 
 
Loss of p65 results in accumulation of hematopoietic stem cells and extramedullary 
hematopoiesis. 
To determine if the loss of p65 leads to defects in hematopoiesis in vivo, 
hematopoietic stem cells were examined. The percentage of KLSF cells was increased by 
approximately 5-fold in p65hem-/- mice.  More specifically, all HSC populations increased, 
including short- and long-term HSCs (Figures 5.2A and 5.2B).  This increase in HSCs 
correlates with a decreased percentage of common myeloid progenitors (CMP), 
granulocyte/monocyte progenitors (GMP), and megakaryocyte/erythrocyte progenitors 
(MEP) (Figures 5.2C and 5.2D).  Due to the increased frequency of HSCs in the bone 
marrow, HSC homing to the spleen and extramedullary hematopoiesis were then monitored.  
Spleens of p65hem-/- animals showed a significant increase in HSCs (Figures 5.3A and 5.3B), 
and displayed extramedullary hematopoiesis (Figure 5.3C).  Histological analysis was 
performed on femurs from p65hem-/- or wild-type counterparts to determine if fibrosis was 
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impacting HSC frequencies and localization to the spleen.  Bones from p65hem-/- animals were 
notably smaller, but fibrosis was not observed (Figure 5.3D).  Proliferation of p65 null HSCs 
is increased, possibly accounting for the accumulation of these cells in both the bone marrow 
and spleen (Figure 5.3E). These data suggest that p65 is required for HSC homeostasis and 
the regulation of hematopoiesis. 
 
p65 is not required for HSC self-renewal or differentiation. 
Due to the increase in HSCs and myeloid progenitors in the bone marrow, lineage-
committed hematopoietic cells were also analyzed to monitor defects in differentiation.  
p65hem-/- animals live a normal life span (data not shown), and develop basic lineages of 
differentiated hematopoietic cells in their bone marrow (Figure 5.4A).  p65-/- HSCs are also 
capable of repopulating all lineages of hematopoietic cells in bone marrow transplant 
recipients (Figure 5.4B).  To ensure that cells that repopulated recipients had not escaped p65 
deletion, total splenocytes were analyzed by immunoblot 20-weeks post-transplant, and 
found to be null of p65 (Figure 5.4C).  Interestingly, p65-/- HSCs do not form colonies as 
efficiently in a cytokine-rich environment in vitro (Figure 5.4D).  Lastly, p65hem-/- mice 
exhibit altered blood cell counts, displaying a myelomonocytic phenotype, with a substantial 
increase in total white blood cells (WBC) and monocytes, and mild thrombocytopenia, 
indicate by a decrease in platelets (Figure 5.4E).  These data show that p65 is not required for 
HSC self-renewal, but that loss of p65 may decrease differentiation efficiency of multipotent 
progenitors. 
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Deletion of p65 impairs HSC repopulation ability in vivo. 
To test the repopulation potential of HSCs lacking p65, a competitive repopulation 
assay was implemented.  Animals were transplanted with equal numbers of “test” and 
“competitor” cells, and engraftment was measured by flow cytometry 20-weeks post 
transplant.  HSCs lacking p65 were not able to reconstitute transplant recipients in a 
competitive situation (Figure 5.5A).  Next, a competitive repopulation assay with limiting 
dilution was used to determine how greatly loss of p65 impacts repopulation potential.  
Again, HSCs lacking p65 showed a decrease in repopulation ability, but were able to 
reconstitute animals when 5-fold more test cells were injected with competitors, at about 
50% of normal capacity (Figure 5.5B).  These data show that p65 is required for HSC 
function, possibly to induce differentiation of HSCs to repopulate recipients. Bone marrow 
chimeras are viable for >6 months (data not shown), suggesting that HSC self-renewal is not 
abolished by the loss of p65, and that HSC exhaustion does not occur. 
 
p65 is not required for the survival of HSCs. 
The accumulation of HSCs and decreased repopulation efficiency by p65 null HSCs 
could be due to death of HSCs or progenitors.  p65 is known to induce survival in the 
presence of inflammatory cytokines, such as TNFα (Beg and Baltimore, 1996), and 
furthermore, previous work has suggested that IKKβ activity is key for the survival of 
hematopoietic progenitors (Mankan et al., 2011).  Apoptosis of bone marrow HSPCs from 
p65hem-/- mice and or littermate controls was measure by flow cytometry.  An unexpectedly 
large percentage of the HSPC fraction underwent apoptosis in the wild-type cells, probably 
due to extended processing time, while the cells lacking p65 were protected from apoptosis 
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(Figure 5.5C).  Interestingly, these data suggest that p65 deletion protects cells from, rather 
than induces, apoptosis in the HSPC fraction.  Protection from apoptosis could be one 
mechanism by which HSCs accumulate in the bone marrow of p65hem-/- in order to 
compensate for decreased function. 
 
Repopulation defects in the absence of p65 are not due to inadequate homing. 
Another potential defect in repopulation efficiency by p65-/- HSC could be due to 
decreased homing efficiency.  After intravenous injection, transplanted HSCs must home to 
the bone marrow niche (Nilsson et al., 2001).  We therefore measured the homing of 
hematopoietic cells to the bone marrow of transplant recipients.  Levels of chimerism were 
equivalent 48-hours after injection of either wild-type or p65-/- hematopoietic cells (Figure 
5.5D) (Adams et al., 2006; Zhao et al., 2009), indicating that loss of p65 does not effect 
homing efficiency of hematopoietic cells, although this assay is not specific to HSC 
localization to the bone marrow niche. 
These data indicate that p65 is important, but not required, for HSCs to repopulate a 
transplant recipient due (Figure 5.5B), and that p65-/- HSCs cannot form colonies in vitro as 
efficiently in the presence of required cytokines (Figure 5.4D).  Long-term survival (>6 
months) of bone chimeras engrafted with p65-/- HSC indicated that HSC self-renewal is not 
abolished by the loss of p65.  However, competitive repopulation assay data suggests that 
self-renewal may be diminished in p65 null HSCs.  The differentiation of hematopoietic 
progenitor cells into lineage-committed cells is also impaired in the absence of p65.  These 
factors would effectively decrease the ability of HSCs to self-renewal and give rise to 
lineage-committed cells, causing them to be outcompeted by healthy HSCs at equal numbers. 
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HSC accumulation is due to cell intrinsic factors. 
The bone marrow niche is known to regulate HSC quiescence, differentiation, and 
localization (Wilson and Trumpp, 2006; Trumpp et al., 2010).  In order to determine if the 
accumulation of HSCs is due to changes in the microenvironment, bone marrow from p65hem-
/- mice or littermate controls was transplanted into lethally irradiated recipients.  20 weeks 
post-transplant, bone marrow was harvested for analysis by flow cytometry.  The percentage 
of HSCs increased by approximately 4-fold in the bone marrow of animals receiving p65-/- 
cells (Figure 5.6A). 
The accumulation of HSCs is also inducible upon loss of p65 or inhibition of IKKβ.  
Recipients were engrafted with cells from Mx1-Cre+p65fl/fl mice or littermate controls.  Mx1 
will drive the expression of Cre upon induction by interferon or poly(I:C), a synthetic analog 
of double-stranded RNA (Kühn et al., 1995).  Recipients were induced with poly(I:C), and, 6 
weeks post-induction, bone marrow was harvested for analysis by flow cytometry.  The 
percentage of HSCs was increased by approximately 6-fold in animals null for p65 in the 
hematopoietic compartment after induction (Figure 5.6B).  Excision of p65 was nearly 
complete in total bone marrow of recipients that received Mx1-Cre+ cells (Figure 5.6C).  
Lastly, the accumulation of HSCs was also induced by IKKβ inhibition.  Healthy, age- and 
sex-matched B6 mice were treated with Compound A, and small molecular inhibitor of IKKβ 
(Ziegelbauer et al., 2005), as described.  The percentage of HSCs cells increased by 
approximately 5-fold in animals that received Compound A rather than vehicle control 
(Figure 5.5D).  Our results show that decreased stem cell efficiency is intrinsic to the cell, 
and is not impacted by the microenvironment. 
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Deletion of p65 results in expression changes of genes involved in HSC homeostasis and 
fate. 
Thus far, our data demonstrate that p65 is an important regulator of early 
hematopoiesis, impacting the function of cells through decreased efficiency to differentiate 
into lineage-restricted cells.  To determine how p65 impacts HSCs, we analyzed changes in 
gene expression in response to loss of p65.  HSCs were sorted and RNA was used for 
microarray analysis.  Results show that loss of p65 results in a significant change in gene 
expression (Figure 5.7A).  The majority of these genes influence cell fate, and predominately 
encode a myeloid differentiation program (Figure 5.7B), while other genes are involved in 
HSC quiescence (Figures 5.7B and 5.7C).  Interestingly, the gene expression profile of HSCs 
lacking p65 more closely resembles that of later hematopoietic progenitors (Figure 5.7C, left) 
than long-term hematopoietic stem cells (Figure 7C, middle).  Lastly, p65-/- HSCs correlate 
strongly with highly proliferative cells rather than quiescent HSCs (Figure 5.7C, right).  
Furthermore, loss of p65 lead to the downregulation of key factors including Mpl, involved 
in HSC quiescence, and Hlf, involved in enhanced HSC function (Figures 5.7B and 5.7D).  
Normally, long-term hematopoietic stem cells express Mpl, also known as the 
thrombopoietin receptor, to maintain a quiescent population capable of self-renewal.  
Deletion of Mpl from animals leads to defects in HSC function and long-term reconstitution 
potential (Kimura et al., 1998).  Thus, the downregulation of Mpl in the absence of p65 could 
at least partially reduce the function of HSCs.  Concurrently, hepatic leukemia factor (Hlf) is 
downregulated in HSCs lacking p65.  Overexpression of Hlf in primitive human HSCs 
increases reconstitution ability by 4-fold in NOD/SCID mice (Shojaei et al., 2005).  While 
the effect of Hlf deletion in HSCs is not known, it is probable that Hlf is an important factor 
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in HSC function.  These changes in gene expression in p65 null HSCs suggest a potential 
shift toward myeloid differentiation along with pressure to proliferate and differentiate more 
frequently. 
In all, loss of p65 causes an inefficient transition between MPP and CMPs that may 
induce a feedback mechanism, causing HSCs to hyperproliferate and accumulate in the bone 
marrow and spleen.  This accumulation then leads to inappropriate homing to the spleen and 
extramedullary hematopoiesis, while the upregulation of genes involved in a myeloid 
differentiation program, leading to neutrophilia. Together, these data show that p65 is an 
important regulator of genes involved in both fate and function of hematopoietic stem cells 
and is necessary for the maintenance of HSC homeostasis. 
 
Discussion and Future Directions 
 We have explored the role of the NF-κB subunit p65 in hematopoiesis.  Data reveals 
that p65 is a key regulator of hematopoietic development, through the regulation of genes 
involved in HSC homeostasis and fate.  HSCs lacking p65 show defects in repopulation 
ability (Figure 5.5A and 5.5B), and accumulation in the bone marrow and spleen of 
hematopoietic p65 null animals (Figure 5.2A and 5.3A).  Furthermore, when HSCs are 
cultured in the presence of cytokines known to support differentiation, cells lacking p65 form 
fewer colonies (Figure 5.4D).  Proliferation of the HSPC fraction is also effected by the loss 
of p65, in which the number of lineage-Sca-1+c-kit+ cells undergoing DNA synthesis 
increases by approximately 3-fold (Figure 5.3E).  Accordingly, changes in gene expression 
include the upregulation of factors involved in proliferation, and the downregulation of 
factors that promote HSC quiescence (Table 5.1).  However, p65 null HSCs can support 
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long-term hematopoiesis in animals lacking p65 in the hematopoietic compartment, as well 
as transplant recipients reconstituted with p65 null cells (Figures 5.4A and 5.4B), indicating 
that HSC self-renewal is not severely affected.  These data point to potential defects in 
differentiation of the multipotent progenitor in the absence of p65. 
 Loss of p65 also has an impact on the fate of multipotent progenitors.  p65 
hematopoietic null animals display splenomegaly (data not shown; see Chapter 6), 
neutrophilia (Figure 5.4E), and the accumulation of myeloid cells in the spleen (data not 
shown; see Chapter 6), as well as a decrease in the percentage of myeloid progenitors in the 
bone marrow (Figures 5.2C and 5.2D).  These findings fit well with changes in gene 
expression in p65 null HSCs.  Array analysis of HSCs from p65hem-/- mice or wild-type 
counterparts indicates the upregulation of genes associated with a myeloid differentiation 
program and changes in genes that regulate HSC quiescence. 
Although the order events are not clear, we hypothesize that loss of p65 leads to a 
decrease in differentiation efficiency of HSCs and/or multipotent progenitors (MPP).  This 
decrease in differentiation then results in a feedback mechanism that initiates division of 
HSCs to give rise to more MPPs in order to maintain a standard level of cells that successful 
undergo differentiation, thereby maintaining steady-state hematopoiesis.  Activation 
additional factors to compensate for the loss of p65 may then introduce skewed 
differentiation through the upregulated expression of myeloid factors at the transcript level, 
inducing a myeloid shift (discussed in Chapter 6). 
Recent evidence shows that non-canonical NF-κB signaling in hematopoiesis is 
important for both HSC self-renewal and cell fate.  Whole body RelB/p52 knockout animals 
display a severe decrease in the number of functional HSCs in their bone marrow.  Although 
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the number of HSPCs increased by approximately 2-fold in p52/RelB-/- mice, the number of 
long-term stem cells was decreased by 5-fold.  Null HSPCs show very poor engraftment 
efficiency in transplant recipients, although this conclusion does not take into account the 
differences in the number of LT-HSCs between wild-type and dKO donor samples.  Of the 
recipients that did engraft, dKO cells reconstituted of primarily the myeloid lineages of 
hematopoietic cells. Interestingly, our data show that loss of p65 results in similar defects in 
HSC repopulation, although the phenotype of HSCs lacking p65 is far less severe.  While 
HSCs lacking p52/RelB showed no repopulation ability at a ratio of less than 150 dKO to 1 
competitor, p65 null HSCs can reconstitute recipients at a ratio of 5 KO cells to 1 competitor, 
albeit not as well as wild-type cells (Figure 5.4B). 
RelB/p52 null animals begin to die at around 2 months, and all are dead by 10 months 
of age.  Loss of stem cell function in the moribund dKO animals was not examined, and 
could be potentially be attributed to bone marrow failure due to HSC exhaustion over time.  
However, death of these animals may also be ascribed inflammatory cell infiltration of 
organs and granulocytosis, as seen in RelB-/- mice (Weih et al., 1995).  HSC function was 
also not determined in the absence of competitor cells, and therefore the severity of defects in 
self-renewal are not clear.  Lifespan of animals reconstituted with RelB/p52-/- could give 
insight into the role of these factors in HSC self-renewal.  While RelB/p52-/- HSCs are 
capable of differentiating into both myeloid and lymphoid cells, it is also possible that they 
are not able to compete against wild-type cells because they differentiate less efficiently. 
RelB/p52 HSPCs proliferate more rapidly, and upregulate cyclin D1 and 
downregulate the cell cycle inhibitor p27.  p65 null HSPCs also proliferate at a higher rate.  
However, gene expression data show that p65-/- HSCs modulate the expression of several 
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genes specific to HSC quiescence, rather than general cell cycle regulators (Figure 5.7B and 
Table 5.1).  Gene expression analysis of the RelB/p52-/- HSCs could help to outline the 
similarities and differences in behavior in comparison to p65-/- HSCs. 
Due to the model system, in which p52 and RelB were knocked out in all cells, 
effects on the microenvironment were also studied.  Interestingly, RelB and p52 are 
important for the maintenance HSC quiescence through regulation of gene expression in the 
microenvironment.  Genes important for the regulation of HSC quiescence, including Cxcl2, 
Thpo, and SCF were downregulated in osteoblastic bone-lining cells from RelB/p65-/- mice.  
The data indicate that RelB/p52 activation is important for the maintenance of stromal cells 
in the bone marrow to maintain HSC quiescence (Zhao et al., 2012).   
Other evidence for impaired HSC function was uncovered in experiments where c-
rel/p65-/- fetal liver cells were used to reconstitute lethally irradiated recipients.  Data show 
that all animals injected with c-rel/p65-/- cells succumbed to engraftment failure after 22-
days post-transplant.  The authors conclude that this is due to a defect in precursor 
populations required for short-term engraftment.  Indeed, numbers of CFU-S, the 
compartment in which these precursors reside, were decreased in animals injected with c-
rel/p65 null fetal liver cells (Grossmann et al., 1999).  Due to the short-term duration of these 
experiments, effects of c-rel/p65 deletion of HSC self-renewal were not analyzed. 
Interestingly, gene expression analysis of HSCs from p65hem-/- mice indicated a large 
shift in gene expression.  The majority of changes noted involve factors that probably dictate 
cell fate, such as Irf8, Csf1r and Lcn2, all involved in differentiation of myeloid cell.  One 
notable change in gene expression was that of Mpl, the thrombopoietin receptor, which is 
down regulated by 3-fold in p65 null HSCs.  Normally, HSCs are held in a quiescent state on 
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the endosteal niche by several factors, including thrombopoietin.  Mpl expression is essential 
for the maintenance of HSC quiescence.  Inhibition of Mpl results in a decreased number of 
quiescent HSCs through the induction of cell cycling (Yoshihara et al., 2007).  Therefore, it 
is possible that in the absence of p65, HSCs undergo cycling in response to decreased Mpl 
expression, while simultaneous expression of myeloid-associated genes imparts a myeloid 
differentiation program in cells preparing to differentiate. 
The role of these genes in HSC homeostasis and fate in response to the loss of p65 
remains to be determined.  Future experiments include verification of gene expression 
changes by real-time PCR, as well as protein changes and, in the case of Mpl, surface 
expression.  We hypothesize that downregulation of Mpl leads to increased cycling of HSCs, 
potentially forcing the cells to commit to a lineage prematurely, resulting in granulocytosis.  
If this is true, it may be possible to at least partially rescue stem cell hyperproliferation and 
perhaps engraftment defects by expressing functional Mpl in p65 null HSCs and injecting 
these cells into lethally irradiated recipients.  Expression analysis of genes constituting a 
myeloid program should also be examined in cells rescued with Mpl.  In all, these 
experiments will shed light on the function some of the gene expression changes seen in p65 
null HSCs. 
Further studies are also required to determine how p65 deletion results in modulation 
of HSC self-renewal and fate.  Though our data suggest that HSC self-renewal may be 
hindered by the loss of p65 due to decrease repopulation potential in a competitive situation 
(Figures 5.5A and 5.5B), full reconstitution of hosts and long-term survival of p65hem-/- mice 
indicate that these cells are still functional.  Serial transplantation is required to calculate the 
self-renewal potential of these cells in comparison to the control to determine how severely 
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self-renewal is impacted in the absence of p65.  Through gene expression analysis, we have 
also shown the p65-/- HSCs upregulate myeloid markers and down regulate factors that 
induce quiescence at the transcript level (Figure 5.7B), potentially explaining why p65hem-/- 
mice exhibit neutrophilia in the peripheral blood (Figure 5.4E).  However, it is probable that 
other compensatory factors have become activated in response to the loss of p65.  
Investigation into which factors compensate for the loss of p65, and if this compensation 
results in skewed hematopoiesis, are needed to determine exactly how p65 activation is 
required in hematopoiesis. 
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Figure 5.1.  Characterization of p65 hematopoietic null mice.  A. Breeding scheme for the 
generation of p65hem-/- mice.  B. p65 expression in whole bone marrow cells or  C. 
hematopoietic stem cells (lineage-Flk2-Sca-1+c-kit+ fraction) of p65hem-/- mice or littermates 
was analyzed by qRT-PCR and.  D. Whole splenocytes from p65hem-/- mice or littermates 
were analyzed for p65 protein expression. 
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Figure 5.2.  p65 deletion results in deregulation of hematopoietic stem and progenitor 
homeostasis.  A. Bone marrow cells were analyzed for hematopoietic stem cell frequency by 
flow cytometry.  B. The average number of cells per genotype is displayed.  C. Bone marrow 
cells were analyzed for hematopoietic progenitor cell frequency using flow cytometry.  D. 
The average number of cells per genotype is displayed.  * = p<0.05 
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Figure 5.3.  Loss of p65 results in the accumulation of hematopoietic stem cells in the 
spleen.  A. Splenocytes were analyzed for hematopoietic stem cell frequency using flow 
cytometry.  B. The average number of cells per genotype is displayed.  C. Spleens were 
stained with H&E for histological analysis.  The arrow indicates a region of extramedullary 
hematopoiesis.  D. Femurs were stained with H&E for histological analysis to monitor 
fibrosis.  E. HSPC cell division was measured used EdU detection.  The average percentage 
of EdU+ (proliferating) HSPCs is shown. 
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Figure 5.4: p65 is not required for self-renew or differentiation of HSPCs.  A. 
Bone marrow of p65hem-/- mice or littermates was analyzed for the frequency of 
lineage-committed cells by flow cytometry.  B. 5x106 whole bone marrow cells from 
p65hem-/- mice or littermate controls were transplanted into lethally irradiated 
recipients.  20 weeks post-transplant, bone marrow was harvested the frequency of 
lineage-committed cells analyzed by flow cytometry.  C.  Spleens were harvested 
from recipients used in 5.4B and analyzed for the expression of p65 by 
immunoblotting.  D.  100 KLSF cells were culture in methylcellulose media with 
cytokines for 10 days.  Colonies were then counted.  *"="p<0.05""E. A complete blood 
panel was performed on peripheral blood collected via cardiac puncture from p65hem-/- 
and wild-type counterparts. 
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Figure 5.5. Deletion of p65 greatly reduces the repopulation ability of hematopoietic 
stem cells.  A.  1x106 test cells (CD45.2), from p65hem-/- mice or littermate controls, were 
injected into lethally irradiated recipients along with 1x106 healthy competitor cells 
(CD45.1).  Engraftment was determined by virtue of CD45.1 and CD45.2 markers in the 
peripheral blood (and bone marrow, data not shown) of recipients 20-weeks post-transplant.  
B. Varying numbers of test cells (1x104, 1x105 or 1x106, as labeled, all CD45.2), from 
p65hem-/- mice or littermate controls, were injected into lethally irradiated recipients along 
with 2x105 healthy competitor cells (CD45.1).  Engraftment was determined by virtue of 
CD45.1 and CD45.2 markers in the peripheral blood (and bone marrow, data not shown) of 
recipients 20-weeks post-transplant.  C. Apoptosis of HSPCs was analyzed by Annexin V 
staining.  D. 2x107 whole bone marrow cells were injected into the lateral tail vein of lethally 
irradiated mice.  Engraftment of donor cells in the bone marrow of recipients was analyzed 
48-hours post-transplant. 
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Figure 5.6.  The accumulation of hematopoietic stem cells in the absence of p65 is cell 
intrinsic.  A. 5x106 whole bone marrow cells from p65hem-/- mice or littermate controls were 
transplanted into lethally irradiated recipients.  20 weeks post-transplant, the frequency of 
bone marrow KLSF cells was monitored by flow cytometry.  B. 3x106 whole bone marrow 
cells from Mx1-Cre+p65fl/fl mice or littermate controls were transplanted into lethally 
irradiated recipients.  6 weeks post-transplant, recipients were injected with 250µg poly(I:C) 
three times, every other day.  6 weeks post-induction, the frequency of bone marrow KLSF 
cells was analyzed by flow cytometry.  C. p65 expression was examined in whole bone 
marrow cells from animals receiving poly(I:C).  D. Bone marrow from animals treated with 
the IKKβ inhibitor compound A was analyzed by flow cytometry to determine the frequency 
of HSPCs. 
  
0 
0.05 
0.1 
0.15 
0.2 
0.25 
WT KO 
Av
er
ag
e 
%
 o
f T
ot
al
 
Po
pu
la
tio
n 
A B 
C 
0"
0.01"
0.02"
0.03"
0.04"
0.05"
0.06"
0.07"
0.08"
WT" KO"
Av
er
ag
e'
%
'P
op
ul
a.
on
'
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
1.4"
WT" KO"
R
el
at
iv
e 
Ex
pr
es
si
on
 
D 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
KLSF LSK 
Av
er
ag
e 
%
 P
op
ul
at
io
n 
NT 
DMSO 
CpA 
 122 
 
 
Figure 7. p65 is an important regulator of gene expression in HSCs.  A. RNA from sorted 
KLSF cells of individual p65hem-/- or wild-type counterparts was used for microarray analysis.  
A heat map indicating changes of a least 2-fold with a p value ≤ 0.01 is shown.  B. A 
representative table of relevant changes in gene expression C. The gene expression profile of 
p65-/- HSCs was compared to those of long-term HSCs (top), late hematopoietic progenitors 
(middle), and dividing hematopoietic cells (bottom) by GSEA using curated gene lists. D. 
The expression of genes involved in homeostasis of HSCs was confirmed by qRT-PCR. 
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Irf8 3.2 Regulation of lineage 
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differentiation 
Met 3.70 Induces proliferation 
Tgm2 -2.2 Upregulated in LT-HSCs 
Hlf -2.4 Increases repopulation 
potential of HSCs 
Mpl -3.0 Regulates HSC quiescence 
and interaction with niche 
D 
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Table 5.1. Specific genes affected by the loss of p65 in HSCs. 
 
Gene 
Symb
ol 
RefSeq 
 
Fold-
Change 
(WT vs. 
KO) 
p-value 
 
Role 
 
Function 
 
 
 
Source 
Elane NM_015779 15.7765 9.69E-05 Fate 
Serine proteinase secreted by 
neutrophils and macrophages 
during inflammation. 
(Belaaouaj, 2000) 
Ly6c1 NM_010741 10.5165 0.000388277 Fate 
Expressed on monocytes and 
neutrophils. 
(Jutila et al., 1994) 
Ly86 NM_010745 8.3891 0.000168266 Fate Expressed on monocytes. Entrez 
Ly6c2 
NM_00109921
7 7.56238 0.000943613 Fate 
Expressed on monocytes and 
neutrophils. 
(Jutila et al., 1994) 
Lcn2 NM_008491 6.61767 0.00064121 Fate 
Early marker of granulocytic 
differentiation 
(Lin et al., 2005) 
Igsf6 NM_030691 5.07356 2.11E-05 Fate 
Novel member of 
immunoglobulin superfamily 
expressed in myeloid cells. 
(Bates et al., 2000) 
Alas1 NM_020559 4.79816 0.000107157 Fate 
Catalyzes an enzyme 
involved in the mammalian 
heme biosynthetic pathway.  
Entrez 
Mpeg1 NM_010821 4.54955 0.000618279 Fate 
Expressed at high levels in 
macrophages. 
(Spilsbury et al., 
1995) 
Prtn3 NM_011178 4.20776 0.000217362 Fate 
Serine protease enzyme 
expressed mainly in 
neutrophil granulocytes. 
(van der Geld et al., 
2001) 
Fcgr3 NM_010188 3.66234 0.00969337 Fate 
Expressed on myeloid 
progenitors. 
(Bryder et al., 2006) 
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Clec5a NM_001038604 3.61885 0.00742043 Fate 
Cell surface receptor 
involved in the activation of 
myeloid cells. 
(Bakker et al., 
1999) 
Csf1r NM_001037859 3.30262 0.000805837 Fate 
Controls the production, 
differentiation, and function 
of macrophages. 
Entrez 
Irf8 NM_008320 3.20171 0.0033933 Fate 
Transcription factor that 
plays critical roles in the 
regulation of lineage 
commitment and in myeloid 
cell maturation including the 
decision for a common 
myeloid progenitor (CMP) 
to differentiate into a 
monocyte precursor cell. 
(Holtschke et al., 
1996) 
Cd53 NM_007651 2.85313 0.00183807 Fate 
Pan leukocyte surface 
marker 
(Wright et al., 
1993) 
Tox NM_145711 -2.79822 0.00113952 Fate 
Nuclear factor required for 
the development of CD4 T 
lineages 
(Aliahmad and 
Kaye, 2008) 
Tgm2 NM_009373 -2.15926 0.00830367 Fate 
Cross linking enzyme 
upregulated by long-term 
HSCs 
(Forsberg et al., 
2005) 
Cish NM_009895 -2.07706 0.00532212 Fate 
Cytokine-inducible negative 
regulators of cytokine 
signaling; proteasome-
mediated degradation of this 
protein has been shown to be 
involved in the inactivation 
of the erythropoietin 
receptor 
Entrez 
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Hp NM_017370 -14.4511 4.30E-05 Function 
Binds free hemoglobin (Hb) 
released from erythrocytes 
with high affinity and thereby 
inhibits its oxidative activity 
Entrez 
Clec12
a NM_177686 7.1022 0.00131627 Function 
Negative regulator of 
granulocyte and monocyte 
function. 
Entrez 
Ctsg NM_007800 6.85508 4.34E-05 Function 
Protease found in granules of 
neutrophilic 
polymorphonuclear 
leukocytes. 
Entrez 
Trem3 NM_021407 6.19565 
0.00025126
5 Function 
Activating receptor on mouse 
macrophages 
(Chung et al., 
2002) 
Ccr2 NM_009915 5.77282 0.00400004 Function 
Mediates monocyte 
chemotaxis. 
Entrez 
F13a1 NM_028784 5.67793 0.00125685 Function Coagulation factor Entrez 
Prssl1 NM_001042710 4.76513 5.81E-05 Function 
Member of the trypsin family 
of serine proteases. 
Entrez 
Hpse NM_152803 3.42578 
0.00077453
4 Function Anti-coagulant 
Entrez 
Adam
22 NM_0010072 -2.25915 0.00013923 Function 
Metalloprotease-domain 
containing protein 
Entrez 
Fcer1a NM_010184 8.29807 1.84E-05 Inflammation 
Couples allergen and mast 
cell to initiate the 
inflammatory and immediate 
hypersensitivity responses. 
Entrez 
Gm88
5 NM_001033435 4.23125 0.00100069 Inflammation 
Inhibits immunoglobulin E-
mediated immediate 
hypersensitivity reactions 
(Hitomi et al., 
2010) 
Ms4a2 NM_013516 3.35507 0.00649585 Inflammation 
Binds allergen to receptor-
bound IgE to initiate cell 
activation. 
Entrez 
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Hdc NM_008230 3.20949 0.00708241 Inflammation 
Converts L-histidine to 
histamine. 
Entrez 
Ms4a3 NM_133246 11.2065 
0.00025125
3 Proliferation 
Hematopoietic cell cycle 
regulator. 
Entrez 
Pyhin1 NM_175026 9.49189 0.00485994 Proliferation 
HIN-200 family member, 
primarily nuclear and 
involved in transcriptional 
regulation of genes important 
for cell cycle control, 
differentiation, and apoptosis. 
RefSeq 
Anxa3 NM_013470 8.35001 
0.00028775
2 Proliferation 
Annexin A3, calcium-
dependent phospholipid-
binding protein family play a 
role in the regulation of 
cellular growth and in signal 
transduction pathways. 
Entrez 
Met NM_008591 3.69873 
0.00083017
3 Proliferation 
Plays a crucial role as a 
hematopoietic regulator in the 
proliferation and 
differentiation of 
hematopoietic progenitors. 
(Nishino et al., 
1995) 
Mpl NM_001122949 -3.00379 0.00753549 Proliferation 
Thrombopoietin receptor, 
regulates HSC quiescence 
and interaction with niche. 
(Yoshihara et al., 
2007) 
(Kimura et al., 
1998) 
Plag1 NM_019969 -3.9198 0.00238723 Proliferation 
Transcription factor whose 
activation can result in 
uncontrolled cell 
proliferation. 
Uniprot 
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Hlf NM_172563 -2.44096 0.00724162 Proliferation 
Hepatic leukemia factor; 
enhanced repopulation 
potential and inhibits apoptosis 
in human hematopoietic stem 
cells; activate the LMO2 
promoter necessary for 
initiation of mammalian 
embryonic hematopoiesis 
(Shojaei et al., 2005) 
Klhl4 NM_172781 -2.06582 0.00285201 Proliferation 
Participates in cell 
proliferation, cell migration 
and cell-matrix interactions via 
its receptor for extracellular 
matrix proteins 
Entrez 
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Supplementary table 5.1.  Flow cytometry antibodies. 
 
Antibody Clone Company 
CD34 RAM34 eBiosciences 
Flk2 A2F10 eBiosciences 
Sca-1 D7 eBiosciences 
FcγRII/III 93 eBiosciences 
c-kit 2B8 eBiosciences 
Lineage cocktail 145-2C11 
RA3-6B2 
M1/70 
RB6-8C5 
TER-119 
eBiosciences 
IgM RMM-1 Biolegend 
CD3 145-2C11 eBiosciences 
B220 RA3-6B2 eBiosciences 
CD11b M1/70 eBiosciences 
Gr-1 RB6-8C5 eBiosciences 
CD45.1 A20 Biolegend 
CD45.2 104 Biolegend 
Annexin V  eBiosciences 
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CHAPTER VI 
 
COMPENSATORY JAK/STAT SIGNALING IN THE ABSENCE OF THE NF-κB 
SUBUNIT p65 
 
Abstract 
 Deletion of the NF-κB subunit p65 results in neutrophilia and other defects in 
hematopoiesis.  Here, we investigate other signaling pathways that may act in a 
compensatory manner in response to p65 deletion, resulting in deregulated myeloid cell 
homing or development.  In the absence of p65, Stat3 is constitutively phosphorylated on its 
activating residue, tyrosine 705.  The activation of Stat3 in p65 null splenocyte correlates 
with the accumulation of myeloid cells in the spleens of p65 hematopoietic null animals.  
Interestingly, the phosphorylation of Stat3 appears to occur in the absence of Jak2, its 
classical activator, which is undetectable in the soluble protein fraction of p65-/- splenocytes 
and p65 -/- mouse embryonic fibroblasts.  We hypothesize that p65 is important for the 
regulation of Jak2 at the post-translational level, and that Stat3 may compensate for p65 to 
promote survival of myeloid cell while driving excess granulopoiesis. 
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Introduction 
 Hematopoiesis is a tightly regulated process in which the hematopoietic stem cells 
give rise to all lineages of blood cells while maintaining the ability to self-renew.  Defects in 
this process can lead to disease, such as leukemias, where cells proliferate in an uncontrolled 
manner, or autoimmune disorders (Bryder et al., 2006).  Many different transcription factors 
are known to control cell fate during hematopoiesis.  Notch1, for example, is involved in 
HSC self-renewal (Zhu and Emerson, 2002) and when inactivated in HSCs in mice, results in 
a myeloproliferative disorder similar to chronic myelomonocytic leukemia (Klinakis et al., 
2011).  Gata-2 is required for maintenance of HSCs, and is sometimes overexpressed in acute 
myeloid leukemia, correlating with poor prognosis (Vicente et al., 2012). 
 Previous data indicate that the NF-κB family of transcription factors may also 
regulate HSC homeostasis and cell fate (see Chapter 5; (Zhao et al., 2012)).  NF-κB is a 
family of dimeric transcription factors comprised of five family members, p65 (RelA), RelB, 
c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2).  These proteins share a conserved Rel 
homology domain, which controls DNA binding, dimerization and interaction with inhibitory 
IκB proteins.  In the classical NF-κB signaling pathway, the subunits p50 and p65 are held in 
an inactive state by IκBα.  Upon stimulation, the activation of the IκB kinase (IKK) complex 
occurs, causing IKKβ to phosphorylate IκBα, resulting in its ubiquitination and subsequent 
degradation.  In the alternative pathway, IKKα homodimers are activated and subsequently 
phosphorylate p100.  This results in the proteolytic processing of p100 to p52 and allows 
p52/RelB to translocate to the nucleus.  Once free of its inhibitor, NF-κB is able to 
translocate to the nucleus where it regulates the expression of a variety of genes, including 
 135 
those encoding cytokines and cytokine receptors, and inflammatory and antiapoptotic 
proteins (Hayden and Ghosh, 2004; Bassères and Baldwin, 2006). 
Systemic deletion of the NF-κB subunits p52 and RelB, which are involved in non-
canonical signaling, in animals results in hematopoietic stem cell defects, due to cell intrinsic 
factors and changes in supportive cues from the microenvironment (Zhao et al., 2012).  Loss 
of the NF-κB subunit, p65, also results in stem cell defects, such as decreased repopulation 
potential, accumulation of HSCs in the bone marrow, and impaired colony formation in vitro 
(Stein and Baldwin, unpublished data; see Chapter 5).  Other evidence for impaired HSC 
function was uncovered in experiments where c-rel/p65-/- fetal liver cells were used to 
reconstitute lethally irradiated recipients where poor engraftment was attributed to defects in 
precursor populations required for short-term engraftment (Grossmann et al., 1999). 
Loss of either classical or alternative NF-κB signaling also results in other defects in 
hematopoiesis, including extramedullary hematopoiesis and granulocytosis.  Hematopoietic 
conditional IKKβ deletion animals develop granulocytosis and splenomegaly (Greten et al., 
2004).  Granulocytosis in these animals has been attributed to a cytokine feedback loop, 
where TNFα-dependent apoptosis of myeloid progenitors leads to the release of IL-1β, which 
promotes the Th17 polarization of peripheral CD4+ T cells.  These cells release IL-17, 
inducing the production of granulocyte colony stimulating factor (G-CSF) and granulocyte-
macrophage colony stimulating factor (GM-CSF), and subsequent proliferation of myeloid 
cells (Mankan et al., 2011).  RelB-/- mice also develop myeloid hyperplasia (Weih et al., 
1995), as do mice engrafted with fetal liver cells from c-rel-/- rela-/- animals (Grossmann et 
al., 1999).  Conditional deletion of TAK1, an upstream activator of NF-κB, also results in 
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granulocytosis and splenomegaly (Alagbala Ajibade et al., 2012).  Taken together, these 
studies suggest that NF-κB is an important regulator of myeloid cell development. 
 Compensatory action by other signaling pathways in response to the deletion of NF-
κB could result in skewed lineage development during hematopoiesis. One such pathway is 
the Jak/Stat pathway, which regulates the expression downstream of inflammatory signaling 
(Yu and Jove, 2004), and shares many gene targets with p65.  Stat3 and p65 regulate of many 
of the same genes involved in cell survival, inflammation and proliferation (Yu et al., 2009).  
Stat3 and p65 are thought to cooperate in cancers, where NF-κB drives the expression of 
cytokines, such as IL-6, which activate STAT3 to drive inflammation and survival.  STAT3 
and p65 are also thought to cooperate at the promoters of genes that encode pro-tumorigenic 
factors through the recruitment of co-activators to promote transcription (Lee et al., 2009). 
The Jak/Stat pathway in normally activated in response to extrinsic cues, such as 
cytokine receptor activation.  Activation of receptor-associated tyrosine kinases, often 
members of the Jak family, results in the phosphorylation of the cytoplasmic tails of cytokine 
receptors on specific tyrosine residues.  These phosphorylated residues provide docking sites 
for the SH2 domains of inactive cytoplasmic Stat monomers that are recruited to the 
activated receptors. Stat monomers are then phosphorylated on activating tyrosine residues 
by Jak, and form dimers through reciprocal phosphotyrosine–SH2 interactions between 
monomers (Figure 6.1).  Stats are negatively regulated by the suppressor of cytokine 
signaling (SOCS) family of proteins, which competitively bind receptors to inhibit Stat 
activation, as well as protein inhibitors of activated Stat (PIAS) proteins, which block Stat 
DNA-binding activity (Yu and Jove, 2004). 
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 Here, we investigate Jak/Stat signaling in response to loss of p65 in non-transformed 
cells.  Data show that deletion of p65 results in alteration of Jak2, potentially though 
subcellular localization or cleavage, but not through proteasomal degradation.  Results also 
indicate that Stat3 is constitutively phosphorylated in splenocytes from p65hem-/- animals, or 
animals treated with an IKKβ inhibitor.  Finally, the activation of Stat3 and modification of 
Jak2 correlate with an increase in immature myeloid cells and myeloid precursors in the 
spleen of mice in the absence or inhibition of NF-κB classical signaling. 
 
Materials and Methods 
Cell lines and treatments.  Wild-type and p65-/- mEFs were cultured in Dulbecco's 
modiﬁed Eagle's medium supplemented with 10% fetal-bovine serum, 4.5g/L glucose and 
0.584g/L L-Glutamine.  mEFs were plated at an equal density and then treated with 10µg 
MG132 (Calbiochem) or EtOH (vehicle control). 
Animal husbandry and drug treatment.  Vav-Cre (B6.Cg-Tg(Vav1-cre)A2Kio/J; stock 
#008610) and B6 (C57BL/6J; stock #000664) mice were obtained from Jackson labs.  p65 
conditional mice have been described previously (Steinbrecher et al., 2008).  B6 mice 
received daily intraperitoneal injections of the IKKβ inhibitor compound A (10mg/kg) or 
vehicle control for 2 weeks.  All animals were housed in accordance with protocols approved 
by the University of North Carolina Institutional Animal Care and Use Committee.  Control 
animals included p65fl/fl littermates (herein: littermates), or Vav-Cre+ p65WT/WT mice (herein: 
wild-type counterparts), as indicated. 
Flow cytometry.  Spleens were gently disrupted with frosted glasses slides, subjected to 
RBC lysis and passed through a 70µm filter.  After processing, splenocytes were Fc blocked 
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where appropriate and then stained with fluorochrome- or biotin-conjugated antibodies.  In 
some instances, streptavidin-conjugated secondary antibodies were used.  A list of antibodies 
used is included as supplementary information in Chapter 5. Samples were analyzed on a 
Beckman-Coulter CyAn ADP.  All flow cytometry data was analyzed using TreeStar FlowJo. 
Histopathologic analysis. Spleens were fixed in 10% saline-buffer formalin, paraffin 
embedded and sectioned.  Sections were then stained with hematoxylin and eosin or pY705 
STAT3 (Cell Signaling Technologies). 
Immunoblotting.  Processed splenocytes were resuspended in lysis buffer (20 mM Tris-HCl, 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton-X, 2.5 mM sodium 
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, protease cocktail (Sigma), 
phosphatase inhibitor (Sigma)) and incubated on ice for 15 minutes.  Equal amounts of 
clarified lysates were subjected to SDS-PAGE, transferred onto a nitrocellulose membrane, 
blocked for 1 hour at room temperature in tris buffered saline with 0.05% Tween-20 and 5% 
non-fat milk, and incubated with the indicated antibodies overnight.  Blots were incubated 
with the appropriate secondary antibody for 1 hour at room temperature and developed using 
ECL detection reagent (GE, Buckinghamshire, UK).  Primary antibodies used for blotting 
were p65 and b-actin, both from Cell Signaling Technologies. 
Fluorescent microscopy.  mEFs were grown on lysine-coated glass coverslips.  Cells were 
fixed in 4% paraformaldehyde, permeabilized with methanol, blocked, and then stained with 
an antibody to pY705 Stat3 (Cell Signaling Technologies #9145) overnight at 4 degrees 
following the manufacturer’s protocol.  Cells were wash in PBS, incubated with an 
AlexaFluor 488-conjugated secondary antibody, and then mounted on slides with Prolong 
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Gold Antifade Reagent with DAPI (Invitrogen).  Images were collected on an Olympus 
BX61 microscope. 
Quantitative Real-time PCR.  Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA), digested with DNase I (Promega, Madison, WI), and used for reverse 
transcription (SuperScript II kit, Invitrogen). All Taqman primers were obtained from 
Applied Biosystems (Foster City, CA).  Expression levels of GusB were used to normalize 
the amount of the investigated transcripts. 
 
Results 
Generation of p65 hematopoietic null animals 
 Conventional deletion of p65 results in embryonic lethality due to liver apoptosis 
induced by TNFα (Beg and Baltimore, 1996).  Therefore, to determine the role of Jak/Stat 
signaling in the absence of p65 in vivo, we utilized hematopoietic null p65 animals (see 
Chapter 5).  Conditional p65 knockouts (loxP-p65 mice) were crossed with mice expressing 
Cre under the control of the vav1 promoter (Figure 6.2A).  Vav is an adaptor protein 
expressed mainly in the hematopoietic system, including the stem cell fraction (Almarza et 
al., 2004; de Boer et al., 2003).  The resulting progeny (p65hem-/- mice) are hematopoietic null 
for p65.  Splenocytes from these animals do not express p65 (Figure 6.2B), indicating that 
p65 is efficiently deleted in this model. 
 
Phenotypic analysis reveals a role for p65 in the regulation of granulopoiesis. 
 Gross phenotypic analysis indicated that p65hem-/- animals develop splenomegaly, with 
an increase of about 1.5-fold in spleen weight over littermate controls (Figure 6.3A).  
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Histology shows that the loss of p65 leads to extramedullary hematopoiesis, with an increase 
in megakaryocytes and the accumulation of hematopoietic “islands” (Figure 6.3B).  Further 
staining to confirm cell type(s) present in these islands is ongoing.  However, flow cytometry 
data suggests that these cells are probably of myeloid origin.  Deletion of p65 results in the 
accumulation of immature myeloid cells (Figure 6.3C and 6.3D) and a statistically 
insignificant increase granulocyte/monocyte progenitors (GMP; Figure 6.3E and 6.3F) in the 
spleen.  Similar analysis of animal treated with an IKKβ inhibitor, compound A, yielded the 
same results.  Healthy, wild-type animals displayed splenomegaly (Figure 6.4A) and the 
accumulation of myeloid cells in the spleen (6.4B) after two weeks of treatment.   Therefore, 
classical NF-κB activity, through both IKKβ and p65, is important for the regulation of 
neutrophil maturation and localization. 
 
Stat3 may compensate for the loss of p65 in myeloid development. 
 We next sought to determine what factors might be leading to the neutrophilia seen in 
the p65hem-/- mice.  The Stats are a family of dimeric transcription factors that are activated in 
response to the stimulation of a variety of cell surface receptors (Yu et al., 2007).  Activation 
of Stat3 occurs through phosphorylation at tyrosine 705, often by the non-receptor tyrosine 
kinase Jak2, allowing monomers to dimerize by virtue of reciprocal SH2 domains (see Figure 
6.1).  Once activated, Stat3 regulates the expression of many genes that overlap with those 
regulated by p65.  Indeed, in the absence of p65, Stat3 phosphorylation at its activating 
residue is increased in total splenocytes (Figure 6.5A).  Interestingly, upon investigation of 
Jak2 activation, we did not observe any phosphorylation at its activating residues.  Total 
protein expression by immunoblot showed that Jak2 is not expressed, at least in the soluble 
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protein fraction, in p65-/- splenocytes (Figure 6.5B).  However, expression of Jak2 
transcripts was not affected (Figure 6.5C).  The phosphorylation of Stat3 and loss of Jak2 
expression is also induced in splenocytes of animals treated with compound A (Figure 6.5D).  
Unexpectedly, the alteration of Jak2 expression correlates with an increase in Stat3 
phosphorylation in the absence of p65, indicating that Jak2 is either sequestered and not 
detected using these methods, or that another factor is activating Stat3. 
 
Loss of p65 results in post-translational modification of Jak2. 
 To determine potential mechanisms of Jak2 loss at the protein level, we utilized p65 
null mouse embryonic fibroblasts (mEFs) along with wild-type controls from littermates.  
p65 null mEFs also display decreased expression of Jak2 protein in the soluble fraction 
(Figure 6.6A).  Treatment with the proteasome inhibitor MG132 did not lead to stability of 
Jak2 in the soluble protein fraction (Figure 6.6B), indicating that Jak2 is not degraded by the 
proteasome in the absence of p65.  Due to the accumulation of a smaller species of Jak2 in 
p65 null or compound A-treated splenocytes as seen by immunoblot (Figure 6.5B and 6.5D), 
we measured post-transcriptional splicing of Jak2 by quantitative real-time PCR using exon-
spanning primer sets.  Analysis shows that all assayed exon junctions are present in Jak2 in 
the absence of p65 in both splenocytes and mEFs (Figure 6.6C and 6.6D), and that Jak2 
transcripts are not being spliced prior to translation.  Together, these data show that p65 
affects Jak2 at the protein level, not post-translation, but not through proteasome-inhibition. 
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Conclusion and Future Directions 
 Here, we have investigated the role of Jak/STAT signaling as a compensatory action 
upon loss of p65.  Data show that animals null for p65 in the hematopoietic compartment 
(Figure 6.2) display splenomegaly (Figure 6.3A) and the accumulation of myeloid cells in the 
spleen (Figure 6.3C and 6.3D).  These cells may be present due to the production of 
neutrophils during extramedullary hematopoiesis in the spleen (Figure 6.3B), or due to 
inappropriate homing at the progenitor stage or later.  Interestingly, the loss of p65 and 
neutrophilia correlates with an increase in Stat3 phosphorylation at its activation tyrosine 
residue (Figure 6.4A).  These phenotypes can also be induced in healthy animals after 
treatment with a small molecular inhibitor of IKKβ (Figure 6.4C).  Unexpectedly, the 
activation of Stat3 correlates with decreased expression of Jak2 at the protein level, at least in 
the soluble fraction.  Transcript levels of Jak2 are not affected by the loss of p65 (Figure 
6.5D, Figure 6.6C and 6.6D).  Proteasomal inhibition does not stabilize Jak2, indicating that 
proteasomal degradation is also not responsible for the loss of Jak2. 
 While neither splicing nor proteosomal degradation appear to impact the expression 
of Jak2, there are many other factors that could effect Jak2 expression.  The first hypothesis 
is that Jak2 is cleaved by an unknown protease in the absence of p65.  Immunoblot analysis 
of Jak2 in splenocytes null of p65 indicates the presence of a band of about 35 kilodaltons.  
The antibody used for the experiment detects the C-terminal end of the protein in between 
the pseudokinase and kinase regions (see Figure 6.8).  The use of a second Jak2 antibody that 
recognizes the pseudokinase of Jak2 detects a band at about 90 kilodaltons in the p65-/- 
splenocytes, and full length Jak2 in the wild-type splenocytes (Figure 6.8).  Together, these 
fragments constitute a protein of 125 kilodaltons, the molecular weight of Jak2. 
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Jak2 cleavage has been proposed in response to DNA damage as a mediator of 
apoptosis.  These findings show that Jak2 is cleaved at a region similar to the area suspected 
to be involved in the absence of p65 (Nagao et al., 2011).  However, multiple non-specific 
bands in the wild-type samples probed with the N-terminal Jak2 antibody bring into question 
the specificity of the band in the p65-/- samples (Figure 6.8).  Nonetheless, a potential reason 
for expression changes of Jak2 could be due to cleavage by a specific protease that is 
normally regulated, either directly or indirectly, by p65 (Figure 6.7).  A cleavage at this 
region would release the kinase domain of Jak2 from the regulatory pseudo-kinase domain, 
which inhibits Jak2 activation through direct binding (Saharinen et al., 2000), potentially 
allowing constitutive tyrosine kinase activity.  Deregulation of Jak2 through deletion or 
mutation of the pseudokinase region results in constitutive kinase activity (Saharinen et al., 
2000; Levine et al., 2005).  In polycythemia vera, a myeloproliferative disorder, most 
patients are positive for the JAK2V617F mutation, which is thought to release the kinase 
domain from the inhibitory interaction with the pseudokinase domain (Levine et al., 2005).  
As Jak2 normally phosphorylates Stat3, continuous activation of Stat3 in the absence of Jak2 
regulation may lead to the unrestricted expression of Stat3 target genes. 
A second hypothesis for modified Jak2 protein expression in the absence of p65 is 
that Jak2 is localized to a non-soluble fraction of the cell, such as a plasma membrane.  The 
samples show in Figures 6.5A-C and 6.6A-B were lysed under less stringent conditions, in a 
1% detergent based buffer (see methods).  A cell based screen for compounds that inhibited 
Jak2 activation uncovered WP1130, a small molecule that inhibits Jak2 through 
ubiquitination, followed by the shuttling of Jak2 to aggresomes near the nucleus (Kapuria et 
al., 2011).  To investigate the formation of Jak2 aggregates in the absence of p65, mEFs were 
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stained with a Jak2 antibody and analyzed by fluorescent microscopy.  Preliminary results 
show that Jak2 does appear to localize in aggregates near the nucleus in p65-/- mEFs (Figure 
6.9).  Further analysis is required to determine the validity of these results. 
This hypothesis also highlights the question of what kinase is phosphorylating Stat3.  
One possibility is a constitutively active Jak2 kinase-domain-only fragment. While Jak2 is 
known to phosphorylate Stat3 in the classical signaling cascades, other JAK family members, 
including Jak1, Jak3 and Tyk2, can phosphorylate Stat3 (Leonard and O'Shea, 1998).  In 
addition, SRC family members are also shown to phosphorylate Stat3 at tyrosine 705 in 
breast and lung cancers and melanoma (Yu and Jove, 2004).  More investigation into which 
of these players are activated in the absence of p65, and if that activation influences Stat3 
phosphorylation, is needed. 
Lastly, the role that Stat3 activation plays in neutrophilia of hematopoietic p65 null 
mice remains to be determined.  Phosphorylation of Stat3 correlates with the accumulation of 
myeloid cells in the spleens of p65hem-/- mice.  One potential reason for Stat3 in the spleens of 
these animals is that CD11b+Gr-1+ myeloid cells express more phosphorylated Stat3 than 
other cell types.  However, preliminary immunohistochemical staining for tyrosine 705 
phosphorylated Stat3 shows that Stat3 phosphorylation is not restricted to any one region of 
the spleen, but rather it appears ubiquitously (Figure 6.10). 
Conversely, Stat3 could be driving extramedullary hematopoiesis and neutrophil 
production, or neutrophil homing to the spleen.  Stat3 is know to regulate survival in 
response to granulocyte colony stimulating factor (G-CSF) through the upregulation of the 
antiapoptotic gene, Bcl-xL (Smithgall et al., 2000).  Stat3 activation is also necessary for 
accelerated proliferation of granulocytic cells in response to infection (Zhang et al., 2010).  
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Deletion of the suppressor of cytokine signaling-3 (SOCS3), a negative regulator of Stat3, 
results in enhanced proliferation and survival in response to G-CSF signaling in vivo, leading 
to splenomegaly and progenitor cell mobilization (Croker et al., 2004).  Based on this 
evidence, it is possible that Stat3 could drive neutrophilia in p65hem-/- mice through the 
promotion of survival factors.  Normally, NF-κB promotes survival in response to 
unfavorable conditions through the upregulation of antiapoptotic gene targets (Bassères and 
Baldwin, 2006), a role that Stat3 may fill in the absence of p65.  By promoting survival of 
cells in the spleen, Stat3 may inhibit apoptosis of myeloid progenitors induced by TNFα 
(Mankan et al., 2011), resulting in increased myeloid survival.  In all, Stat3 may play a 
compensatory role in the absence of p65 and drive neutrophilia, although further 
investigation is required. 
  
 146 
 
 
Figure 6.1.  The JAK/STAT signaling pathway. 
 
 
 
 
 
 
 
Figure 6.2.  Characterization of p65 hematopoietic null mice.  A. The breeding scheme 
used to generate p65hem-/- mice.  B. Splenocytes from p65hem-/- or wild-type counterparts were 
analyzed for the expression of p65 by immunoblot. 
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Figure 6.3.  Deletion of p65 in vivo causes splenomegaly and granulocytosis.  A. Spleens 
from p65hem-/- mice or wild-type counterparts were weight at 8-10 weeks of age.  B. Spleens 
were stained with H&E for histological analysis. C. Myeloid cells or D. myeloid progenitors 
were analyzed in the spleen by flow cytometry. 
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Figure 6.4. IKKβ inhibition results in splenomegaly and granulocytosis.  Healthy, age 
matched, male B6 mice were treated with the IKKβ inhibitor compound A daily for two 
weeks.  After treatment, spleens were harvested and A. weighed, and B. analyzed by flow 
cytometry for myeloid cell frequency. 
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Figure 6.5. Loss of p65 results in phosphorylation of Stat3 and alteration of Jak2.  A 
and B. Total splenocytes from p65hem-/- mice or littermates were analyzed by immunoblot.  C. 
Splenocytes from healthy animals treated with compound A daily for two weeks were 
analyzed by immunoblot.  D. Jak2 expression in splenocytes from p65hem-/- mice or 
littermates was analyzed by qRT-PCR. 
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Figure 6.6.  p65 null mouse embryonic fibroblasts display alteration of Jak2.  A. Wild-
type or p65-/- mEFs were analyzed by immunoblot.  B. Wild-type or p65-/- mEFs were 
treated with 10µM MG132 or EtOH (vehicle control) over time and analyzed for protein 
stabilization by immunoblot.  C. Splicing of Jak2 was monitored using qRT-PCR in 
splenocytes from p65hem-/- or littermates, or D. p65-/- mEFS. 
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Figure 6.7. Model of the Jak2 cleavage hypothesis. 
 
 
 
 
 
Figure 6.8. Jak2 alteration may be due to cleavage by an unknown protease.  Total 
splenocytes from p65hem-/- or littermates were analyzed by immunoblot. 
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Figure 6.9. Jak2 localization is altered in p65-/- mEFs.  Wild-type or p65-/- mEFs were 
stained for Jak2 and analyzed by fluorescent microscopy. 
 
 
 
Figure 6.10. Phosphorylation of Stat3 at tyrosine 705 is ubiquitous in spleens from 
p65hem-/- mice.  Spleen sections were stained with pY705 Stat3 and analyzed by microscopy. 
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CHAPTER VII 
 
CONCLUSIONS 
 
 The goal of this thesis research has been to determine the potential therapeutic value 
of targeting NF-κB in chronic myeloid leukemia (CML).  While CML, which is driven by the 
BCR-ABL oncoprotein, is currently treated with the BCR-ABL inhibitor imatinib, 
complications can arise through drug resistance.  Therefore, discovery of novel therapeutics 
for CML is important for the treatment and eradication of drug resistant CML cells.  Previous 
work has shown that BCR-ABL activates NF-κB, and that its activation is required for tumor 
formation in nude mice (Reuther et al., 1998).  Given these results, we sought to test the 
efficacy of NF-κB inhibition in drug-resistant CML models. 
Drug resistance in CML can occur through a variety of mechanisms.  One mechanism 
involves mutations in BCR-ABL, rendering it resistant to competitive kinase domain 
blocking inhibitors through conformational changes (Schindler et al., 2000).  One mutation, 
in which threonine 315 is mutated to a isoleucine (T315I), results in complete resistance to 
current BCR-ABL inhibitors (Gorre et al., 2001).  Our data show that treatment with 
compound A, a small molecule inhibitor of IKKβ, results in death of BCR-ABL-expressing 
cell lines, including those expressing the T315I mutation (Chapter 2).  We went on to show 
that BCR-ABL-expressing cells undergo apoptosis in response to both IKKβ and direct NF-
κB inhibition induced by the c-jun N-terminal kinase (JNK) pathway (Chapter 3).  These data 
indicated that NF-κB is a promising potential therapeutic target for drug resistant CML. 
CML stem cells, a primitive population of cancer stem cells that has escaped the 
normal control of self-renewal, drive the disease (Kavalerchik et al., 2008).  CML stem cells 
are refractory to all known BCR-ABL inhibitors (Copeland et al., 2006).  Due to the 
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favorable results of IKKβ inhibition in drug resistant CML cells in vitro, we are currently 
testing the ability of an IKKβ inhibitor, compound A, to target leukemic stem cells in vivo 
(Chapter 4; see Figures 4.6 and 4.7).  Preliminary results indicate that compound A can 
effective block colony formation by BCR-ABL-transformed primary hematopoietic stem and 
progenitors cells in vitro, and that NF-κB is important for BCR-ABL-driven transformation 
of these cells.  The effect of compound A treatment on CML stem cells in vivo remains to be 
determined (see Figure 4.6). 
CML cells are also supported through micro-environmental cues that normally 
regulate the maintenance of hematopoietic stem cells (HSCs) in the endosteal niche in the 
bone marrow (Trumpp et al., 2010).  Results show that leukemic stem cells that are resistant 
to imatinib treatment remain dormant (Graham et al., 2002), which may be regulated by 
factors secreted in the microenvironment.  While the role of the microenvironment in 
imatinib-resistant CML is an area of ongoing debate, it is clear that drug treatment studies 
must also be performed in vivo to account for the contribution of micro-environmental cues 
in CML.  Using a genetic model of p65 deletion, we will induce p65 excision in BCR-ABL-
expressing cells in animals that have developed CML (see Figure 4.7).  As a secondary 
approach, sick animals will also be treated with compound A.  Together, these data will 
indicate the involvement, if any, of micro-environmental cues that render BCR-ABL-
expressing cells resistant to IKKβ inhibition or p65 deletion in vivo, as well as the ability of 
compound A to target quiescent leukemia stem cells. 
A caveat of uncovering novel therapeutic targets for disease is that those targets are 
often important in functions required by normal, healthy cells.  For example, NF-κB 
activation is important in response to inflammation, where it inhibits apoptosis in response to 
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transient inflammatory signals.  This function is required for the survival of animals in utero 
to protect hepatocytes from TNFα induced apoptosis (Beg and Baltimore, 1996).  Therefore, 
novel therapeutics require testing in healthy individuals to determine toxicity.  To determine 
the role of the classical NF-κB signaling pathway in hematopoiesis, we generated mice null 
of p65 in the hematopoietic compartment (see Figure 5.1).  We found that the loss of p65 
results in deregulation of hematopoiesis through changes in hematopoietic stem cell (HSC) 
homeostasis, fate and function.  Hematopoietic p65 null animals displayed hyperproliferation 
of HSCs in their bone marrow, extramedullary hematopoiesis, and decreased HSC 
repopulation ability, indicating probable defects in both self-renewal and differentiation of 
HSCs.  Importantly, the majority of these phenotypes are also induced in healthy animals 
through treatment with compound A.  Gene expression analysis of hematopoietic stem cells 
from p65 hematopoietic null mice or wild-type counterparts indicates that loss of p65 leads to 
changes in genes that regulate HSC quiescence and fate (Chapter 5; see Figure 5.7).  
Together, these data show that p65 is an important regulator of steady-state hematopoiesis. 
Genetic loss of p65 also induces granulocytosis and splenomegaly in animals.  The 
accumulation of myeloid cells in spleen of these mice correlates with the constitutive 
phosphorylation of Stat3 at its activation residue in the absence of p65.  Interestingly, the 
expression of Jak2, an upstream activator or Stat3, is altered (see Chapter 6).  Investigation 
into the details of this alteration and its effect on downstream signaling events are ongoing.  
However, it appears that Stat3 may act as a compensatory factor in the absence of p65 to 
promote survival of myeloid cells, resulting in granulocytosis. 
This compensation could play a role in granulopoiesis in the bone marrow.  We have 
observed that p65 is expressed at a lower molecular weight in the bone marrow of wild-type 
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animals, at about 40 kilodaltons.  It is possible that, in bone marrow cells, p65 is altered in 
such a way that it is inactivated, allowing for other transcription factors, such as Stat3, to 
regulate the development of myeloid cells in a transient manner.  As bone marrow is made up 
of a heterogeneous cell population, and mature hematopoietic cells home to the periphery in 
most cases, it is possible that p65 is inactivated in the majority of lineage-committed 
precursors, but not in the rare HSPCs, where it is important for self-renewal and 
differentiation. 
Taken together, these results suggest that IKKβ inhibition in drug resistant CML 
should be approached with caution.  Long-term treatment with IKKβ inhibition in patients 
will likely yield undesirable side effects.  However, if IKKβ inhibition is effective in 
eradicating leukemia stem cells in CML, treatment would be transient and the outcome 
permanent.  Further investigation into the effects of NF-κB targeting on leukemia stem cells 
is required to determine if the benefits outweigh the costs of this novel therapeutic in CML 
patients. 
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